

A world of investing.®



# Putnam Global Health Care Fund

Annual report

8 | 31 | 23



This **global sector fund** invests in stocks of health care companies worldwide.

FUND SYMBOL  
CLASS A  
PHSTX

# Putnam Global Health Care Fund

## Annual report

8 | 31 | 23

Message from the Trustees	1
Interview with your fund's portfolio manager	3
Your fund's performance	7
Your fund's expenses	9
Comparative index definitions	11
Other information for shareholders	12
Important notice regarding Putnam's privacy policy	13
Trustee approval of management contracts	14
Audited financial statements	22
Report of Independent Registered Public Accounting Firm	23
Federal tax information	45
About the Trustees	46
Officers	48

## Message from the Trustees

October 6, 2023

Dear Fellow Shareholder:

Stocks rose across most global markets in the 12 months ended August 31, 2023. During this time, the U.S. economy continued to expand despite worries about a potential recession. Enthusiasm over the innovation of generative artificial intelligence helped lift investor sentiment. Stock performance in non-U.S. markets generally lagged U.S. markets. Growth in the eurozone stalled in the winter of 2022–2023 amid Russia’s war against Ukraine, while China’s economy struggled given its heavily indebted property sector.

Bond market performance was mostly lackluster over the period, although some sectors posted gains. The U.S. Federal Reserve has continued to raise interest rates but at a more gradual pace compared with 2022. U.S. inflation has eased but is still above the Fed’s 2% target. Against this backdrop, investors are weighing the impact of high borrowing costs and tighter lending conditions at banks.

As active managers, your investment team continues to research attractive opportunities for your fund while monitoring risks. This report offers an update on their efforts.

Thank you for investing with Putnam.

Respectfully yours,



A handwritten signature in black ink that reads "Robert L. Reynolds".

**Robert L. Reynolds**  
President and Chief Executive Officer  
Putnam Investments




A handwritten signature in black ink that reads "Kenneth R. Leibler".

**Kenneth R. Leibler**  
Chair, Board of Trustees

## Performance history as of 8/31/23

### Annualized total return (%) comparison




Current performance may be lower or higher than the quoted past performance, which cannot guarantee future results. Share price, principal value, and return will fluctuate, and you may have a gain or a loss when you sell your shares. Performance of class A shares assumes reinvestment of distributions and does not account for taxes. Fund returns in the bar chart do not reflect a sales charge of 5.75%; had they, returns would have been lower. See below and pages 7–9 for additional performance information. For a portion of the periods, the fund had expense limitations, without which returns would have been lower. To obtain the most recent month-end performance, visit [putnam.com](http://putnam.com).

\* The fund's benchmark, the MSCI World Health Care Index (ND), was introduced on 1/1/01, which post-dates the inception of the fund's class A shares.

All MSCI indices are provided by MSCI.

### Recent broad market index and fund performance



This comparison shows your fund's performance in the context of broad market indexes for the 12 months ended 8/31/23. See above and pages 7–9 for additional fund performance information. Index descriptions can be found on page 11.

All Bloomberg indices are provided by Bloomberg Index Services Limited.

All MSCI indices are provided by MSCI.

## Interview with your fund's portfolio manager

Mike Maguire discusses the investing environment and fund performance for the 12 months ended August 31, 2023, as well as his outlook for health care stocks.



**Michael J. Maguire, CFA**  
Portfolio Manager

Mike has an M.B.A. from Carnegie Mellon University and a B.S. in Accounting from Boston College. He joined Putnam in 2009 and has been in the investment industry since 2001.

### **Mike, please describe investing conditions during the reporting period.**


Stocks weathered multiple headwinds, including stubborn inflation, rising interest rates, slowing global growth, and the Russia-Ukraine War. In March 2023, the failure of several U.S. regional banks also rattled markets. Swift action by policymakers helped to minimize systemic risk and calm investor nerves.

Over the period, the U.S. Federal Reserve continued to raise interest rates to combat high inflation. By December 2022, the Fed began to reduce the size and pace of its interest-rate hikes as inflation gradually declined. Investors grew hopeful that the U.S. would avoid a recession. Positive corporate earnings and a strong U.S. labor market further boosted investors' appetite for stocks. In calendar 2023, a rally in large-cap technology stocks, driven by interest in artificial intelligence, drove the bulk of returns in the U.S. stock market. The S&P 500 Index returned 15.94% for the 12-month reporting period.

Within the health care sector, stock performance was mixed. Inflationary pricing and supply chain disruptions remained challenging for many companies across the sector. New health care reforms like the Inflation Reduction

## Global composition

● United States	70.0%
● Denmark	8.5
● United Kingdom	5.8
● France	5.1
● Japan	3.0
● Canada	0.8
● Netherlands	0.7
● Cash and net other assets	6.1



Allocations are shown as a percentage of the fund's net assets as of 8/31/23. Cash and net other assets, if any, represent the market value weights of cash, derivatives, short-term securities, and other unclassified assets in the portfolio. Summary information may differ from the information in the portfolio schedule notes included in the financial statements due to the inclusion of derivative securities, any interest accruals, the exclusion of as-of trades, if any, and rounding. Holdings and allocations may vary over time. Due to rounding, percentages may not equal 100%.

## Top 10 holdings

HOLDING (PERCENTAGE OF FUND'S NET ASSETS)	COUNTRY
UnitedHealth Group, Inc. (8.7%)	United States
Eli Lilly and Co. (7.3%)	United States
AstraZeneca PLC (5.8%)	United Kingdom
Intuitive Surgical, Inc. (5.4%)	United States
Sanofi (5.1%)	France
AbbVie, Inc. (5.0%)	United States
Novo Nordisk A/S Class B (5.0%)	Denmark
Thermo Fisher Scientific, Inc. (4.5%)	United States
Innoviva, Inc. (4.3%)	United States
Boston Scientific Corp. (4.0%)	United States

This table shows the fund's top 10 holdings by percentage of the fund's net assets as of 8/31/23. Short-term investments and derivatives, if any, are excluded. Holdings may vary over time.

Act [IRA] also weighed on investor sentiment. The IRA will allow the U.S. government to negotiate certain prescription drug prices directly with Medicare. While the IRA could help some Medicare recipients lower their drug spending, some investors believe it puts downward pricing pressure on drug manufacturers and may reduce funding used to develop new drugs. As investors digested the impact of the IRA, stocks of large-cap pharmaceuticals, managed care companies, and insurers faced sell-offs in the latter half of the period.

Health care utilization rates rose sharply in calendar 2023. Hospitals and medical facilities shed the last of their Covid restrictions, driving up demand for elective surgeries, outpatient visits, and routine screenings. Stocks of companies that supply surgical equipment, medical devices, and diagnostic tools began to outperform those in other health care industries. Higher-than-expected utilization costs squeezed the profit margins of managed care companies, and their stocks moved lower. Stocks of pre-revenue, early-stage biotechnology companies declined from their pandemic highs, as many of these companies struggled to secure financing amid higher interest rates. On the positive side, an uptick in M&A activity by large-cap pharmaceuticals helped lift biotech stocks before period-end.

### **How did the fund perform for the reporting period?**

The fund returned 11.79%, outperforming its benchmark, the MSCI World Health Care Index [ND], which returned 10.09% for the period.

### **What were some stocks that helped fund performance during the reporting period?**

Intuitive Surgical, a U.S.-based manufacturer and developer of robotic products used in minimally invasive surgery, was the fund's top contributor. Intuitive is considered the pioneer of robotic-assisted surgery and a global technology leader in minimally invasive care. The company's flagship product, the da Vinci Surgical System, is used in a growing number

## **“ Innovation remains the main driver of our research focus and stock selection. ”**

of procedures, including cardiac, urologic, gynecologic, pediatric, and general surgery. As surgery volumes rose in 2023, demand for Intuitive's systems increased. Intuitive reported strong quarterly earnings in the first two quarters of calendar 2023.

Global pharmaceutical company Eli Lilly was another top performer. Lilly has a large diabetes franchise that serves a global population of over 460 million people with type 2 diabetes. In 2023, Lilly set its sights on entering the obesity treatment space. In clinical trials, the company's diabetic drug tirzepatide, branded as Mounjaro, helped some patients lose over 20% of their body weight. In October 2022, Lilly received a Fast Track designation from the U.S. Food and Drug Administration [FDA] to accelerate the review of Mounjaro as an obesity therapeutic. Lilly expects the FDA will approve Mounjaro's new indication for use in chronic weight management by year-end 2023, which provided a tailwind for its stock.

### **What were some stocks that detracted from fund performance during the reporting period?**

Innoviva, a health care royalty management company, was among the fund's top detractors. The company generates royalty revenue streams from a portfolio of GlaxoSmithKline respiratory products. Innoviva is now focused on developing a pipeline of therapeutic assets, including antibiotics, used in hospital settings. The company's entry into the biotechnology space contributed to investor uncertainty, and the stock moved lower. We believe the long-term growth trends related to antibiotics are promising, and we continue to own the stock.

UnitedHealth Group, a U.S. managed health care and insurance company, also was a detractor. The stock faced downward pressure

when the company reported a reduction in its operating margins in the second quarter of calendar 2023. The company attributed the decline to higher-than-expected utilization rates caused by pent-up demand for routine and elective surgeries post-pandemic. While margins declined, the company's fastest-growing business, Optum, contributed strong revenues and earnings growth year over year. As a technology and managed services solutions provider, Optum positions UnitedHealth with a long runway for growth, in our view. We continue to own the stock.

### **What is your outlook for the health care sector and the fund?**

We believe pharmaceutical, biotech, and medical device companies will continue to have inflationary cost pressures, at least until the Fed winds down its rate-hiking cycle. For health care providers, labor challenges have been pervasive, driving up wage inflation and lowering their profit margins.

We believe new regulations like the IRA will have widespread implications across the health care sector over the next several years. During the period, the U.S. government released the

names of the first 10 drugs whose prices may be lowered for Medicare patients beginning in 2026. We will continue to evaluate the impact of these reforms across the sector.

For the fund, innovation remains the main driver of our research focus and stock selection. From pharma and biotech to devices and providers, we dig deep with extensive due diligence, including meetings and conversations with medical experts, physicians, and company managements. Through active management of the fund, we can take advantage of price dislocations occurring in the marketplace. Overall, we have a constructive outlook for the global health care sector.

### **Thank you, Mike, for your time and insights today.**

*The views expressed in this report are exclusively those of Putnam Management and are subject to change. They are not meant as investment advice.*

*Please note that the holdings discussed in this report may not have been held by the fund for the entire period. Portfolio composition is subject to review in accordance with the fund's investment strategy and may vary in the future. Current and future portfolio holdings are subject to risk.*



## Your fund's performance

This section shows your fund's performance, price, and distribution information for periods ended August 31, 2023, the end of its most recent fiscal year. In accordance with regulatory requirements for mutual funds, we also include performance information as of the most recent calendar quarter-end and expense information taken from the fund's current prospectus. Performance should always be considered in light of a fund's investment strategy. Data represent past performance. Past performance does not guarantee future results. More recent returns may be less or more than those shown. Investment return and principal value will fluctuate, and you may have a gain or a loss when you sell your shares. Performance information does not reflect any deduction for taxes a shareholder may owe on fund distributions or on the redemption of fund shares. For the most recent month-end performance, please visit the Individual Investors section at [putnam.com](http://putnam.com) or call Putnam at 1-800-225-1581. Class R, R6, and Y shares are not available to all investors.

### Annualized fund performance Total return for periods ended 8/31/23

	Life of fund	10 years	5 years	3 years	1 year
<b>Class A (5/28/82)</b>					
Before sales charge	11.52%	10.83%	9.86%	7.84%	11.79%
After sales charge	11.36	10.18	8.57	5.73	5.36
<b>Class B (3/1/93)</b>					
Before CDSC	11.31	10.17	9.04	7.02	10.94
After CDSC	11.31	10.17	8.85	6.44	6.34
<b>Class C (7/26/99)</b>					
Before CDSC	11.36	10.17	9.04	7.02	10.96
After CDSC	11.36	10.17	9.04	7.02	9.98
<b>Class R (1/21/03)</b>					
Net asset value	11.25	10.56	9.59	7.57	11.51
<b>Class R6 (6/1/20)</b>					
Net asset value	11.69	11.15	10.21	8.21	12.19
<b>Class Y (4/4/00)</b>					
Net asset value	11.68	11.11	10.14	8.11	12.07

Current performance may be lower or higher than the quoted past performance, which cannot guarantee future results. After-sales-charge returns for class A shares reflect the deduction of the maximum 5.75% sales charge levied at the time of purchase. Class B share returns after contingent deferred sales charge (CDSC) reflect the applicable CDSC, which is 5% in the first year, declining over time to 1% in the sixth year, and is eliminated thereafter. Class C share returns after CDSC reflect a 1% CDSC for the first year that is eliminated thereafter. Class R, R6, and Y shares have no initial sales charge or CDSC. Performance for class B, C, R, and Y shares before their inception is derived from the historical performance of class A shares, adjusted for the applicable sales charge (or CDSC) and the higher operating expenses for such shares, except for class Y shares, for which 12b-1 fees are not applicable. Performance for class R6 shares prior to their inception is derived from the historical performance of class Y shares and has not been adjusted for the lower investor servicing fees applicable to class R6 shares; had it, returns would have been higher.

For a portion of the periods, the fund had expense limitations, without which returns would have been lower. Class B and C share performance reflects conversion to class A shares after eight years.

## Comparative annualized index returns For periods ended 8/31/23

	Life of fund	10 years	5 years	3 years	1 year
MSCI World Health Care Index (ND)	—*	10.08%	8.21%	6.54%	10.09%

Index results should be compared with fund performance before sales charge, before CDSC, or at net asset value.

\* The fund's benchmark, the MSCI World Health Care Index (ND), was introduced on 1/1/01, which post-dates the inception of the fund's class A shares.


All MSCI indices are provided by MSCI.

## Change in the value of a \$10,000 investment (\$9,425 after sales charge)

Cumulative total return from 8/31/13 to 8/31/23

Putnam Global Health Care Fund class A shares after sales charge

MSCI World Health Care Index (ND)



Past performance does not indicate future results. At the end of the same time period, a \$10,000 investment in the fund's class B and C shares would have been valued at \$26,341 and \$26,340, respectively, and no contingent deferred sales charges would apply. A \$10,000 investment in the fund's class R, R6, and Y shares would have been valued at \$27,284, \$28,770, and \$28,676, respectively.

All MSCI indices are provided by MSCI.

## Fund price and distribution information For the 12-month period ended 8/31/23

Distributions	Class A	Class B	Class C	Class R	Class R6	Class Y
Number	1	1	1	1	1	1
Income	\$0.081	—	—	—	\$0.282	\$0.239
Capital gains						
Long-term gains	4.379	\$4.379	\$4.379	\$4.379	4.379	4.379
Short-term gains	—	—	—	—	—	—
<b>Total</b>	<b>\$4.460</b>	<b>\$4.379</b>	<b>\$4.379</b>	<b>\$4.379</b>	<b>\$4.661</b>	<b>\$4.618</b>
<b>Share value</b>	<b>Before sales charge</b>	<b>After sales charge</b>	<b>Net asset value</b>	<b>Net asset value</b>	<b>Net asset value</b>	<b>Net asset value</b>
8/31/22	\$55.47	\$58.85	\$23.43	\$35.23	\$50.30	\$61.35
8/31/23	57.43	60.93	21.52	34.62	51.60	63.84

The classification of distributions, if any, is an estimate. Before-sales-charge share value and current dividend rate for class A shares, if applicable, do not take into account any sales charge levied at the time of purchase. After-sales-charge share value, current dividend rate, and current 30-day SEC yield, if applicable, are calculated assuming that the maximum sales charge (5.75% for class A shares) was levied at the time of purchase. Final distribution information will appear on your year-end tax forms.

## Annualized fund performance as of most recent calendar quarter

Total return for periods ended 9/30/23

	Life of fund	10 years	5 years	3 years	1 year
<b>Class A (5/28/82)</b>					
Before sales charge	11.46%	10.26%	9.25%	7.59%	15.18%
After sales charge	11.30	9.61	7.97	5.49	8.56
<b>Class B (3/1/93)</b>					
Before CDSC	11.25	9.60	8.44	6.80	14.31
After CDSC	11.25	9.60	8.25	6.22	9.58
<b>Class C (7/26/99)</b>					
Before CDSC	11.30	9.60	8.44	6.79	14.33
After CDSC	11.30	9.60	8.44	6.79	13.33
<b>Class R (1/21/03)</b>					
Net asset value	11.18	9.98	8.98	7.32	14.87
<b>Class R6 (6/1/20)</b>					
Net asset value	11.63	10.57	9.59	7.97	15.57
<b>Class Y (4/4/00)</b>					
Net asset value	11.62	10.53	9.52	7.86	15.46

See the discussion following the fund performance table on page 7 for information about the calculation of fund performance.

## Your fund's expenses

As a mutual fund investor, you pay ongoing expenses, such as management fees, distribution fees (12b-1 fees), and other expenses. Using the following information, you can estimate how these expenses affect your investment and compare them with the expenses of other funds. You may also pay one-time transaction expenses, including sales charges (loads) and redemption fees, which are not shown in this section and would have resulted in higher total expenses. For more information, see your fund's prospectus or talk to your financial representative.

### Expense ratios

	Class A	Class B	Class C	Class R	Class R6	Class Y
Total annual operating expenses for the fiscal year ended 8/31/22	1.05%	1.80%	1.80%	1.30%	0.71%	0.80%
Annualized expense ratio for the six-month period ended 8/31/23*	1.06%	1.81%	1.81%	1.31%	0.72%	0.81%

Fiscal year expense information in this table is taken from the most recent prospectus, is subject to change, and may differ from that shown for the annualized expense ratio and in the financial highlights of this report.

Expenses are shown as a percentage of average net assets.

\* Expense ratios for each class are for the fund's most recent fiscal half year. As a result of this, ratios may differ from expense ratios based on one-year data in the financial highlights.

## Expenses per \$1,000

The following table shows the expenses you would have paid on a \$1,000 investment in each class of the fund from 3/1/23 to 8/31/23. It also shows how much a \$1,000 investment would be worth at the close of the period, assuming *actual returns* and expenses.

	Class A	Class B	Class C	Class R	Class R6	Class Y
Expenses paid per \$1,000*†	\$5.57	\$9.49	\$9.49	\$6.88	\$3.78	\$4.26
Ending value (after expenses)	\$1,083.60	\$1,079.20	\$1,079.20	\$1,082.20	\$1,085.30	\$1,084.80

\* Expenses for each share class are calculated using the fund's annualized expense ratio for each class, which represents the ongoing expenses as a percentage of average net assets for the six months ended 8/31/23. The expense ratio may differ for each share class.

† Expenses are calculated by multiplying the expense ratio by the average account value for the period; then multiplying the result by the number of days in the period (184); and then dividing that result by the number of days in the year (365).

## Estimate the expenses you paid

To estimate the ongoing expenses you paid for the six months ended 8/31/23, use the following calculation method. To find the value of your investment on 3/1/23, call Putnam at 1-800-225-1581.

### How to calculate the expenses you paid

**Value of your investment on 3/1/23** ÷ **\$1,000** X **Expenses paid per \$1,000** = **Total expenses paid**

**Example** Based on a \$10,000 investment in class A shares of your fund.

**\$10,000** ÷ **\$1,000** X **\$5.57** (see preceding table) = **\$55.70**

## Compare expenses using the SEC's method

The Securities and Exchange Commission (SEC) has established guidelines to help investors assess fund expenses. Per these guidelines, the following table shows your fund's expenses based on a \$1,000 investment, assuming a *hypothetical 5% annualized return*. You can use this information to compare the ongoing expenses (but not transaction expenses or total costs) of investing in the fund with those of other funds. All mutual fund shareholder reports will provide this information to help you make this comparison. Please note that you cannot use this information to estimate your actual ending account balance and expenses paid during the period.

	Class A	Class B	Class C	Class R	Class R6	Class Y
Expenses paid per \$1,000*†	\$5.40	\$9.20	\$9.20	\$6.67	\$3.67	\$4.13
Ending value (after expenses)	\$1,019.86	\$1,016.08	\$1,016.08	\$1,018.60	\$1,021.58	\$1,021.12

\* Expenses for each share class are calculated using the fund's annualized expense ratio for each class, which represents the ongoing expenses as a percentage of average net assets for the six months ended 8/31/23. The expense ratio may differ for each share class.

† Expenses are calculated by multiplying the expense ratio by the average account value for the six-month period; then multiplying the result by the number of days in the six-month period (184); and then dividing that result by the number of days in the year (365).

## Comparative index definitions

**Bloomberg U.S. Aggregate Bond Index** is an unmanaged index of U.S. investment-grade fixed income securities.

**ICE BofA (Intercontinental Exchange Bank of America) U.S. 3-Month Treasury Bill Index** is an unmanaged index that seeks to measure the performance of U.S. Treasury bills available in the marketplace.

**MSCI World Health Care Index (ND)** is a free float-adjusted market capitalization-weighted index that is designed to measure the equity market performance of developed markets in the health care sector. Calculated with net dividends (ND), this total return index reflects the reinvestment of dividends after the deduction of withholding taxes, using a tax rate applicable to non-resident institutional investors who do not benefit from double taxation treaties.

**S&P 500® Index** is an unmanaged index of common stock performance.

Indexes assume reinvestment of all distributions and do not account for fees. Securities and performance of a fund and an index will differ. You cannot invest directly in an index.

BLOOMBERG® is a trademark and service mark of Bloomberg Finance L.P. and its affiliates (collectively “Bloomberg”). Bloomberg or Bloomberg’s licensors own all proprietary rights in the Bloomberg Indices. Neither Bloomberg nor Bloomberg’s licensors approve or endorse this material, or guarantee the accuracy or completeness of any information herein, or make any warranty, express or implied, as to the results to be obtained therefrom, and to the maximum extent allowed by law, neither shall have any liability or responsibility for injury or damages arising in connection therewith.

ICE Data Indices, LLC (“ICE BofA”), used with permission. ICE BofA permits use of the ICE BofA indices and related data on an “as is” basis; makes no warranties regarding same; does not guarantee the suitability, quality, accuracy, timeliness, and/or completeness of the ICE BofA indices or any data included in, related to, or derived therefrom; assumes no liability in connection with the use of the foregoing; and does not sponsor, endorse, or recommend Putnam Investments, or any of its products or services.

Certain information contained herein (the “Information”) is sourced from/copyright of MSCI Inc., MSCI ESG Research LLC, or their affiliates (“MSCI”), or information providers (together the “MSCI Parties”) and may have been used to calculate scores, signals, or other indicators. The Information is for internal use only and may not be reproduced or disseminated in whole or part without prior written permission. The Information may not be used for, nor does it constitute, an offer to buy or sell, or a promotion or recommendation of, any security, financial instrument or product, trading strategy, or index, nor should it be taken as an indication or guarantee of any future performance. Some funds may be based on or linked to MSCI indexes, and MSCI may be compensated based on the fund’s assets under management or other measures. MSCI has established an information barrier between index research and certain Information. None of the Information in and of itself can be used to determine which securities to buy or sell or when to buy or sell them. The Information is provided “as is” and the user assumes the entire risk of any use it may make or permit to be made of the Information. No MSCI Party warrants or guarantees the originality, accuracy, and/or completeness of the Information, and each expressly disclaims all express or implied warranties. No MSCI Party shall have any liability for any errors or omissions in connection with any Information herein, or any liability for any direct, indirect, special, punitive, consequential, or any other damages (including lost profits) even if notified of the possibility of such damages.

## Other information for shareholders

### Important notice regarding delivery of shareholder documents

In accordance with Securities and Exchange Commission (SEC) regulations, Putnam sends a single notice of internet availability, or a single printed copy, of annual and semiannual shareholder reports, prospectuses, and proxy statements to Putnam shareholders who share the same address, unless a shareholder requests otherwise. If you prefer to receive your own copy of these documents, please call Putnam at 1-800-225-1581 or, for exchange-traded funds only, 1-833-228-5577. We will begin sending individual copies within 30 days.

### Proxy voting

Putnam is committed to managing our funds in the best interests of our shareholders. The Putnam funds' proxy voting guidelines and procedures, as well as information regarding how your fund voted proxies relating to portfolio securities during the 12-month period ended June 30, 2023, are available in the Individual Investors section of [putnam.com](http://putnam.com) and on the SEC's website, [www.sec.gov](http://www.sec.gov). If you have questions about finding forms on the SEC's website, you may call the SEC at 1-800-SEC-0330. You may also obtain the Putnam funds' proxy voting guidelines and procedures at no charge by calling Putnam's Shareholder Services at 1-800-225-1581 or, for exchange-traded funds only, 1-833-228-5577.

### Fund portfolio holdings

The fund will file a complete schedule of its portfolio holdings with the SEC for the first and third quarters of each fiscal year on Form N-PORT within 60 days of the end of such fiscal quarter. Shareholders may obtain the fund's Form N-PORT on the SEC's website at [www.sec.gov](http://www.sec.gov).

### Trustee and employee fund ownership

Putnam employees and members of the Board of Trustees place their faith, confidence, and, most importantly, investment dollars in Putnam funds. As of August 31, 2023, Putnam employees had approximately \$499,000,000 and the Trustees had approximately \$70,000,000 invested in Putnam funds. These amounts include investments by the Trustees' and employees' immediate family members as well as investments through retirement and deferred compensation plans.

### Liquidity risk management program

Putnam, as the administrator of the fund's liquidity risk management program (appointed by the Board of Trustees), presented the most recent annual report on the program to the Trustees in May 2023. The report covered the structure of the program, including the program documents and related policies and procedures adopted to comply with Rule 22e-4 under the Investment Company Act of 1940, and reviewed the operation of the program from January 2022 through December 2022. The report included a description of the annual liquidity assessment of the fund that Putnam performed in November 2022. The report noted that there were no material compliance exceptions identified under Rule 22e-4 during the period. The report included a review of the governance of the program and the methodology for classification of the fund's investments. Putnam concluded that the program has been operating effectively and adequately to ensure compliance with Rule 22e-4.

## Important notice regarding Putnam's privacy policy

In order to conduct business with our shareholders, we must obtain certain personal information such as account holders' names, addresses, Social Security numbers, and dates of birth. Using this information, we are able to maintain accurate records of accounts and transactions.

It is our policy to protect the confidentiality of our shareholder information, whether or not a shareholder currently owns shares of our funds. In particular, it is our policy not to sell information about you or your accounts to outside marketing firms. We have safeguards in place designed to prevent unauthorized access

to our computer systems and procedures to protect personal information from unauthorized use.

Under certain circumstances, we must share account information with outside vendors who provide services to us, such as mailings and proxy solicitations. In these cases, the service providers enter into confidentiality agreements with us, and we provide only the information necessary to process transactions and perform other services related to your account. Finally, it is our policy to share account information with your financial representative, if you've listed one on your Putnam account.

## Trustee approval of management contracts

### **Consideration of your fund's new and interim management, sub-management and sub-advisory contracts**

At their meeting on June 23, 2023, the Board of Trustees of your fund, including all of the Trustees who are not "interested persons" (as this term is defined in the Investment Company Act of 1940, as amended (the "1940 Act")) of the Putnam mutual funds, closed-end funds and exchange-traded funds (collectively, the "funds") (the "Independent Trustees") approved, subject to approval by your fund's shareholders, a new management contract with Putnam Investment Management ("Putnam Management"), a new sub-management contract between Putnam Management and its affiliate, Putnam Investments Limited ("PIL"), and a new sub-advisory contract among Putnam Management, PIL and another affiliate, The Putnam Advisory Company ("PAC") (collectively, the "New Management Contracts"). The Trustees considered the proposed New Management Contracts in connection with the planned acquisition of Putnam U.S. Holdings I, LLC ("Putnam Holdings") by a subsidiary of Franklin Resources, Inc. ("Franklin Templeton"). The Trustees considered that, on May 31, 2023, Franklin Templeton and Great-West Lifeco Inc., the parent company of Putnam Holdings, announced that they had entered into a definitive agreement for a subsidiary of Franklin Templeton to acquire Putnam Holdings in a stock and cash transaction (the "Transaction"). The Trustees noted that Putnam Holdings was the parent company of Putnam Management, PIL and PAC. The Trustees were advised that the Transaction would result in a "change of control" of Putnam Management, PIL and PAC and would cause your fund's current Management Contract with Putnam Management, Sub-Management Contract with PIL and Sub-Advisory Contract with PAC (collectively, the "Current Management Contracts") to terminate in accordance with the 1940 Act. The Trustees considered that the New Management Contracts would take effect upon the closing of the Transaction, which was expected to occur in the fourth quarter of 2023.

In addition to the New Management Contracts, the Trustees also approved interim management, sub-management and sub-advisory contracts with Putnam Management, PIL and PAC, respectively (the "Interim Management Contracts"), which would take effect in the event that for any

reason shareholder approval of a New Management Contract was not received by the time of the Transaction closing. The Trustees considered that each Interim Management Contract that became effective would remain in effect until shareholders approved the proposed New Management Contract, or until 150 days elapse after the closing of the Transaction, whichever occurred first. The considerations and conclusions discussed in connection with the Trustees' consideration of the New Management Contracts and the continuance of your fund's Current Management Contracts also apply to the Trustees' consideration of the Interim Management Contracts, supplemented by consideration of the terms, nature and reason for any Interim Management Contract.

The Independent Trustees met with their independent legal counsel, as defined in Rule 0-1(a)(6) under the 1940 Act (their "independent legal counsel"), and representatives of Putnam Management and its parent company, Power Corporation of Canada, to discuss the potential Transaction, including the timing and structure of the Transaction and its implications for Putnam Management and the funds, during their regular meeting on November 18, 2022, and the full Board of Trustees further discussed these matters with representatives of Putnam Management at its regular meeting on December 15, 2022. At a special meeting on December 20, 2022, the full Board of Trustees met with representatives of Putnam Management, Power Corporation of Canada and Franklin Templeton to further discuss the potential Transaction, including Franklin Templeton's strategic plans for Putnam Management's asset management business and the funds, potential sources of synergy between Franklin Templeton and Putnam Management, potential areas of partnership between Power Corporation of Canada and Franklin Templeton, Franklin Templeton's distribution capabilities, Franklin Templeton's existing service provider relationships and Franklin Templeton's recent acquisitions of other asset management firms.

In order to assist the Independent Trustees in their consideration of the New Management Contracts and other anticipated impacts of the Transaction on the funds and their shareholders, independent legal counsel for the Independent Trustees furnished an initial information request to Franklin Templeton (the "Initial Franklin Request"). At a



special meeting of the full Board of Trustees held on January 25, 2023, representatives of Franklin Templeton addressed the firm's responses to the Initial Franklin Request. At the meeting, representatives of Franklin Templeton discussed, among other things, the business and financial condition of Franklin Templeton and its affiliates, Franklin Templeton's U.S. registered fund operations, its recent acquisition history, Franklin Templeton's intentions regarding the operation of Putnam Management and the funds following the completion of the potential Transaction and expected benefits to the funds and Putnam Management that might result from the Transaction.

The Board of Trustees actively monitored developments with respect to the potential Transaction throughout the period leading up to the public announcement of a final sale agreement on May 31, 2023. The Independent Trustees met to discuss these matters at their regular meetings on January 27, April 20 and May 19, 2023. The full Board of Trustees also discussed developments at their regular meeting on February 23, 2023. Following the public announcement of the Transaction on May 31, 2023, independent legal counsel for the Independent Trustees furnished a supplemental information request (the "Supplemental Franklin Request") to Franklin Templeton. At the Board of Trustees' regular in-person meeting held on June 22–23, 2023, representatives of Putnam Management and Power Corporation of Canada provided further information regarding, among other matters, the final terms of the Transaction and efforts undertaken to retain Putnam employees. The Contract Committee of the Board of Trustees also met on June 22, 2023 to discuss Franklin Templeton's responses to the Supplemental Franklin Request. Mr. Reynolds, the only Trustee affiliated with Putnam Management, participated in portions of these meetings to provide the perspective of the Putnam organization, but did not otherwise participate in the deliberations of the Independent Trustees or the Contract Committee regarding the potential Transaction.

After the presentations and after reviewing the written materials provided, the Independent Trustees met at their in-person meeting on June 23, 2023 to consider the New Management Contracts for each fund, proposed to become

effective upon the closing of the Transaction, and the filing of a preliminary proxy statement. At this meeting and throughout the process, the Independent Trustees also received advice from their independent legal counsel regarding their responsibilities in evaluating the potential Transaction and the New Management Contracts. The Independent Trustees reviewed the terms of the proposed New Management Contracts and the differences between the New Management Contracts and the Current Management Contracts. They noted that the terms of the proposed New Management Contracts were substantially identical to the Current Management Contracts, except for certain changes designed largely to address differences among various of the existing contracts, which had been developed and implemented at different times in the past.

In considering the approval of the proposed New Management Contracts, the Board of Trustees took into account a number of factors, including:<sup>1</sup>

- (i) Franklin Templeton's and Putnam Management's belief that the Transaction would not adversely affect the funds or their shareholders and their belief that the Transaction was likely to result in certain benefits (described below) for the funds and their shareholders;
- (ii) That Franklin Templeton did not intend to make any material change in Putnam Management's senior investment professionals (other than certain changes related to reporting structure and organization of personnel discussed below), including the portfolio managers of the funds, or to the firm's operating locations as a result of the Transaction;
- (iii) That Franklin Templeton intended for Putnam Management's equity investment professionals to continue to operate largely independently from Franklin Templeton, reporting to Franklin Templeton's Head of Public Markets following the Transaction;
- (iv) That, while Putnam Management's organizational structure was not expected to change immediately following the Transaction, Franklin Templeton intended to revise Putnam Management's reporting structure in order to include Putnam Management's fixed income investment professionals in Franklin Templeton's fixed income group and to include Putnam Management's

---

<sup>1</sup>All subsequent references to Putnam Management describing the Board of Trustees' considerations should be deemed to include references to PIL and PAC as necessary or appropriate in the context.

Global Asset Allocation (“GAA”) investment professionals in Franklin Templeton’s investment solutions group, with both Franklin Templeton groups reporting to Franklin Templeton’s Head of Public Markets;

(v) Franklin Templeton’s expectation that there would not be any changes in the investment objectives, strategies or portfolio holdings of the funds as a result of the Transaction;

(vi) That neither Franklin Templeton nor Putnam Management had any current plans to propose changes to the funds’ existing management fees or expense limitations, or current plans to make changes to the funds’ existing distribution arrangements;

(vii) Franklin Templeton’s and Putnam Management’s representations that, following the Transaction, there was not expected to be any diminution in the nature, quality and extent of services provided to the funds and their shareholders by Putnam Management, PIL and PAC, including compliance and other non-advisory services;

(viii) That Franklin Templeton did not currently plan to change the branding of the funds or to change the lineup of funds in connection with the Transaction but would continue to evaluate how best to position the funds in the market;

(ix) The possible benefits accruing to the funds and their shareholders as a result of the Transaction, including:

a. That the scale of Franklin Templeton’s investment operations platform would increase the investment and operational resources available to the funds;

b. That the Putnam open-end funds would benefit from Franklin Templeton’s large retail and institutional global distribution capabilities and significant network of intermediary relationships, which may provide additional opportunities for the funds to increase assets and reduce expenses by spreading expenses over a larger asset base; and

c. Potential benefits to shareholders of the Putnam open-end funds that could result from the alignment of certain fund features and shareholder benefits with those of other funds sponsored by Franklin Templeton and its affiliates and access to a broader array of investment opportunities;

(x) The financial strength, reputation, experience and resources of Franklin Templeton and its investment advisory subsidiaries;

(xi) Franklin Templeton’s expectation that the Transaction would not impact the capabilities or responsibilities of Putnam Management’s Investment Division (other than any impact related to reporting structure changes for Putnam Management’s equity, fixed income and GAA investment groups and to including Putnam Management’s fixed income and GAA investment professionals in existing Franklin Templeton investment groups, as discussed above) and that any changes to the Investment Division over the longer term would be made in order to achieve perceived operational efficiencies or improvements to the portfolio management process;

(xii) Franklin Templeton’s commitment to maintaining competitive compensation arrangements to allow Putnam Management to continue to attract and retain highly qualified personnel and Putnam Management’s and Franklin Templeton’s efforts to retain personnel, including efforts implemented since the Transaction was announced;

(xiii) That the current senior management teams at Putnam Management and Power Corporation of Canada had indicated their strong support of the Transaction and that Putnam Management had recommended that the Board of Trustees approve the New Management Contracts; and

(xiv) Putnam Management’s and Great-West Lifeco Inc.’s commitment to bear all expenses incurred by the funds in connection with the Transaction, including all costs associated with the proxy solicitation in connection with seeking shareholder approval of the New Management Contracts.

Finally, in considering the proposed New Management Contracts, the Board of Trustees also took into account their concurrent deliberations and conclusions, as described below, in connection with their annual review of the funds’ Current Management Contracts and the approval of their continuance, effective July 1, 2023, and the extensive materials that they had reviewed in connection with that review process.

Based upon the foregoing considerations, on June 23, 2023, the Board of Trustees, including all of the Independent Trustees, unanimously approved the proposed New Management Contracts and determined to recommend their approval to the shareholders of the funds.

## General conclusions — Current Management Contracts

The Board of Trustees oversees the management of each fund and, as required by law, determines annually whether to approve the continuance of your fund's management contract with Putnam Management, the sub-management contract with respect to your fund between Putnam Management and PIL and the sub-advisory contract among Putnam Management, PIL and PAC. (Because PIL and PAC are affiliates of Putnam Management and Putnam Management remains fully responsible for all services provided by PIL and PAC, the Trustees did not attempt to evaluate PIL or PAC as separate entities.) The Board of Trustees, with the assistance of its Contract Committee, requests and evaluates all information it deems reasonably necessary under the circumstances in connection with its annual contract review. The Contract Committee consists solely of Independent Trustees.

At the outset of the review process, members of the Board of Trustees' independent staff and independent legal counsel considered any possible changes to the annual contract review materials furnished to the Contract Committee during the course of the previous year's review and, as applicable, identified those changes to Putnam Management. Following these discussions and in consultation with the Contract Committee, the Independent Trustees' independent legal counsel requested that Putnam Management and its affiliates furnish specified information, together with any additional information that Putnam Management considered relevant, to the Contract Committee. Over the course of several months ending in June 2023, the Contract Committee met on a number of occasions with representatives of Putnam Management, and separately in executive session, to consider the information that Putnam Management provided. Throughout this process, the Contract Committee was assisted by the members of the Board of Trustees' independent staff and by independent legal counsel for the funds and the Independent Trustees.

At the Board of Trustees' June 2023 meeting, the Contract Committee met in executive session to discuss and consider its recommendations with respect to the continuance of the contracts. At that meeting, the Contract Committee also met in executive session with the other Independent Trustees to review a summary of the key financial, performance and other data that the Contract

Committee considered in the course of its review. The Contract Committee recommended, and the Independent Trustees approved, the continuance of your fund's Current Management Contracts, effective July 1, 2023, and the approval of your fund's New Management Contracts and Interim Management Contracts, as discussed above.

The Independent Trustees' approvals were based on the following conclusions:

- That the fee schedule in effect for your fund represented reasonable compensation in light of the nature and quality of the services being provided to the fund, the fees paid by competitive funds, the costs incurred by Putnam Management in providing services to the fund and the application of certain reductions and waivers noted below; and
- That the fee schedule in effect for your fund represented an appropriate sharing between fund shareholders and Putnam Management of any economies of scale as may exist in the management of the fund at current asset levels.

These conclusions were based on a comprehensive consideration of all information provided to the Trustees and were not the result of any single factor. Some of the factors that figured particularly in the Trustees' deliberations and how the Trustees considered these factors are described below, although individual Trustees may have evaluated the information presented differently, giving different weights to various factors. It is also important to recognize that the management arrangements for your fund and the other Putnam mutual funds and closed-end funds are the result of many years of review and discussion between the Independent Trustees and Putnam Management, that some aspects of the arrangements may receive greater scrutiny in some years than others and that the Trustees' conclusions may be based, in part, on their consideration of fee arrangements in previous years. For example, with certain exceptions primarily involving newer funds (including the exchange-traded funds) or repositioned funds, the current fee arrangements under the vast majority of the funds' management contracts were first implemented at the beginning of 2010 following extensive review by the Contract Committee and discussions with representatives of Putnam Management, as well as approval by shareholders. The Trustees also took into account their concurrent deliberations and conclusions, and the materials that they had reviewed, in connection with their approval on June 23, 2023

of the Interim Management Contracts and the New Management Contracts, which had been proposed in light of the Transaction (which would cause the fund's Current Management Contracts to terminate in accordance with applicable law or the terms of each contract).

### **Management fee schedules and total expenses**

The Trustees reviewed the management fee schedules in effect for all funds, including fee levels and any breakpoints. Under its management contract, your fund has the benefit of breakpoints in its management fee schedule that provide shareholders with reduced fee levels as assets under management in the Putnam family of funds increase. The Trustees also reviewed the total expenses of each Putnam fund, recognizing that in most cases management fees represented the major, but not the sole, determinant of total costs to fund shareholders. (Two mutual funds and each of the exchange-traded funds have implemented so-called "all-in" or unitary management fees covering substantially all routine fund operating costs.)

In reviewing fees and expenses, the Trustees generally focus their attention on material changes in circumstances — for example, changes in assets under management, changes in a fund's investment strategy, changes in Putnam Management's operating costs or profitability, or changes in competitive practices in the fund industry — that suggest that consideration of fee changes might be warranted. The Trustees concluded that the circumstances did not indicate that changes to the management fee schedule for your fund would be appropriate at this time.

As in the past, the Trustees also focused on the competitiveness of each fund's total expense ratio. The Trustees, Putnam Management and the funds' investor servicing agent, Putnam Investor Services, Inc. ("PSERV"), have implemented expense limitations that were in effect during your fund's fiscal year ending in 2022. These expense limitations were: (i) a contractual expense limitation applicable to specified mutual funds, including your fund, of 25 basis points on investor servicing fees and expenses and (ii) a contractual expense limitation applicable to specified mutual funds, including your fund, of 20 basis points on so-called "other expenses" (i.e., all expenses exclusive of management fees, distribution fees, investor servicing fees, investment-related expenses, interest,

taxes, brokerage commissions, acquired fund fees and expenses and extraordinary expenses). These expense limitations attempt to maintain competitive expense levels for the funds. Most funds, including your fund, had sufficiently low expenses that these expense limitations were not operative during their fiscal years ending in 2022. Putnam Management and PSERV have agreed to maintain these expense limitations until at least December 30, 2024. Putnam Management and PSERV's commitment to these expense limitation arrangements, which were intended to support an effort to have the mutual fund expenses meet competitive standards, was an important factor in the Trustees' decision to approve your fund's New Management Contracts and Interim Management Contracts and the continuance of your fund's Current Management Contracts.

The Trustees reviewed comparative fee and expense information for a custom group of competitive funds selected by Broadridge Financial Solutions, Inc. ("Broadridge"). This comparative information included your fund's percentile ranking for effective management fees and total expenses (excluding any applicable 12b-1 fees), which provides a general indication of your fund's relative standing. In the custom peer group, your fund ranked in the second quintile in effective management fees (determined for your fund and the other funds in the custom peer group based on fund asset size and the applicable contractual management fee schedule) and in the third quintile in total expenses (excluding any applicable 12b-1 fees) as of December 31, 2022. The first quintile represents the least expensive funds and the fifth quintile the most expensive funds. The fee and expense data reported by Broadridge as of December 31, 2022 reflected the most recent fiscal year-end data available in Broadridge's database at that time.

In connection with their review of fund management fees and total expenses, the Trustees also reviewed the costs of the services provided and the profits realized by Putnam Management and its affiliates from their contractual relationships with the funds. This information included trends in revenues, expenses and profitability of Putnam Management and its affiliates relating to the investment management, investor servicing and distribution services provided to the funds, as applicable. In this regard, the Trustees also reviewed an analysis of the revenues, expenses and profitability of Putnam Management and its affiliates, allocated on a fund-by-fund basis, with

respect to (as applicable) the funds' management, distribution and investor servicing contracts. For each fund, the analysis presented information about revenues, expenses and profitability in 2022 for each of the applicable agreements separately and for the agreements taken together on a combined basis. The Trustees concluded that, at current asset levels, the fee schedules in place for each of the funds, including the fee schedule for your fund, represented reasonable compensation for the services being provided and represented an appropriate sharing between fund shareholders and Putnam Management of any economies of scale as may exist in the management of the funds at that time.

The information examined by the Trustees in connection with their annual contract review for the funds included information regarding services provided and fees charged by Putnam Management and its affiliates to other clients, including collective investment trusts offered in the defined contribution and defined benefit retirement plan markets, sub-advised mutual funds, private funds sponsored by affiliates of Putnam Management, model-only separately managed accounts and Putnam Management's manager-traded separately managed account programs. This information included, in cases where a product's investment strategy corresponds with a fund's strategy, comparisons of those fees with fees charged to the funds, as well as an assessment of the differences in the services provided to these clients as compared to the services provided to the funds. The Trustees observed that the differences in fee rates between these clients and the funds are by no means uniform when examined by individual asset sectors, suggesting that differences in the pricing of investment management services to these types of clients may reflect, among other things, historical competitive forces operating in separate marketplaces. The Trustees considered the fact that in many cases fee rates across different asset classes are higher on average for 1940 Act-registered funds than for other clients, and the Trustees also considered the differences between the services that Putnam Management provides to the funds and those that it provides to its other clients. The Trustees did not rely on these comparisons to any significant extent in concluding that the management fees paid by your fund are reasonable.

## **Investment performance**

The quality of the investment process provided by Putnam Management represented a major factor in the Trustees' evaluation of the quality of services provided by Putnam Management under your fund's management contract. The Trustees were assisted in their review of Putnam Management's investment process and performance by the work of the investment oversight committees of the Trustees and the full Board of Trustees, which meet on a regular basis with individual portfolio managers and with senior management of Putnam Management's Investment Division throughout the year. The Trustees concluded that Putnam Management generally provides a high-quality investment process — based on the experience and skills of the individuals assigned to the management of fund portfolios, the resources made available to them and in general Putnam Management's ability to attract and retain high-quality personnel — but also recognized that this does not guarantee favorable investment results for every fund in every time period.

The Trustees considered that, in the aggregate, peer-relative and benchmark-relative Putnam fund performance was generally encouraging in 2022 against a backdrop of volatile equity and fixed income markets, driven by factors such as Russia's invasion of Ukraine, increased tensions with China, disruptions in energy markets and broader supply chains, rising inflation and the significant tightening of monetary policy by the Board of Governors of the Federal Reserve in an effort to combat inflation. The Trustees further noted that, in the face of these numerous economic headwinds, corporate earnings and employment data had been generally robust throughout 2022. For the one-year period ended December 31, 2022, the Trustees noted that the Putnam funds, on an asset-weighted basis, ranked in the 41st percentile of their peers as determined by Lipper Inc. ("Lipper") and, on an asset-weighted-basis, outperformed their benchmarks by 1.3% gross of fees over the one-year period. The Committee also noted that the funds' aggregate performance over longer-term periods continued to be strong, with the funds, on an asset-weighted basis, ranking in the 34th, 27th and 22nd percentiles of their Lipper peers over the three-year, five-year and ten-year periods ended December 31, 2022, respectively. The Trustees further noted that the funds, in the aggregate, outperformed their benchmarks on a gross basis for each of the three-year, five-year and ten-year

periods. The Trustees also considered the Morningstar Inc. ratings assigned to the funds and that 40 funds were rated four or five stars at the end of 2022, which represented an increase of 15 funds year-over-year. The Trustees also considered that seven funds were five-star rated at the end of 2022, which was a year-over-year decrease of two funds, and that 83% of the funds' aggregate assets were in four- or five-star rated funds at year end.

In addition to the performance of the individual Putnam funds, the Trustees considered, as they had in prior years, the performance of The Putnam Fund complex versus competitor fund complexes, as reported in the Barron's/Lipper Fund Families survey (the "Survey"). The Trustees noted that the Survey ranks mutual fund companies based on their performance across a variety of asset types, and that The Putnam Fund complex had performed exceptionally well in 2022. In this regard, the Trustees considered that the funds had ranked 9th out of 49 fund companies, 3rd out of 49 fund companies and 2nd out of 47 fund companies for the one-year, five-year and ten-year periods, respectively. The Trustees also noted that The Putnam Fund complex had been the only fund family to rank in the top ten in all three time periods. They also noted, however, the disappointing investment performance of some Putnam funds for periods ended December 31, 2022 and considered information provided by Putnam Management regarding the factors contributing to the underperformance and, where relevant, actions being taken to improve the performance of these particular funds. The Trustees indicated their intention to continue to monitor the performance of those funds.

For purposes of the Trustees' evaluation of the Putnam funds' investment performance, the Trustees generally focus on a competitive industry ranking of each fund's total net return over a one-year, three-year and five-year period. For a number of Putnam funds with relatively unique investment mandates for which Putnam Management informed the Trustees that meaningful competitive performance rankings are not considered to be available, the Trustees evaluated performance based on their total gross and net returns and comparisons of those returns to the returns of selected investment benchmarks. In the case of your fund, the Trustees considered information about your fund's total return and its performance relative to its benchmark over the one-year, three-year and five-year periods ended December 31, 2022. Your fund's class A shares'

return, net of fees and expenses, was negative but exceeded the return of its benchmark over the one-year period ended December 31, 2022, and was positive and exceeded the return of its benchmark over the three-year and five-year periods ended December 31, 2022. (When considering performance information, shareholders should be mindful that past performance is not a guarantee of future results.)

The Trustees also considered Putnam Management's continued efforts to support fund performance through certain initiatives, including structuring compensation for portfolio managers to enhance accountability for fund performance, emphasizing accountability in the portfolio management process and affirming its commitment to a fundamental-driven approach to investing.

### **Brokerage and soft-dollar allocations; distribution and investor servicing**

The Trustees considered various potential benefits that Putnam Management may receive in connection with the services it provides under the management contract with your fund. These include benefits related to brokerage allocation and the use of soft dollars, whereby a portion of the commissions paid by a fund for brokerage may be used to acquire research services that are expected to be useful to Putnam Management in managing the assets of the fund and of other clients. Subject to policies established by the Trustees, soft dollars generated by these means are used predominantly to acquire brokerage and research services (including third-party research and market data) that enhance Putnam Management's investment capabilities and supplement Putnam Management's internal research efforts. The Trustees indicated their continued intent to monitor regulatory and industry developments in this area with the assistance of their Brokerage Committee. In addition, with the assistance of their Brokerage Committee, the Trustees indicated their continued intent to monitor the allocation of the funds' brokerage in order to ensure that the principle of seeking best price and execution remains paramount in the portfolio trading process.

Putnam Management may also receive benefits from payments made to Putnam Management's affiliates by the mutual funds for distribution services and investor services. In conjunction with the review of your fund's management, sub-management and sub-advisory contracts,

the Trustees reviewed your fund's investor servicing agreement with PSERV and its distributor's contract and distribution plans with Putnam Retail Management Limited Partnership ("PRM"), both of which are affiliates of Putnam Management. The Trustees concluded that the fees payable by the mutual funds to PSERV and PRM for such services were fair and reasonable in relation to

the nature and quality of such services, the fees paid by competitive funds and the costs incurred by PSERV and PRM in providing such services. Furthermore, the Trustees were of the view that the investor services provided by PSERV were required for the operation of the mutual funds, and that they were of a quality at least equal to those provided by other providers.

## Audited financial statements

**These sections of the report, as well as the accompanying Notes, preceded by the Report of Independent Registered Public Accounting Firm, constitute the fund's audited financial statements.**

**The fund's portfolio** lists all the fund's investments and their values as of the last day of the reporting period. Holdings are organized by asset type and industry sector, country, or state to show areas of concentration and diversification.

**Statement of assets and liabilities** shows how the fund's net assets and share price are determined. All investment and non-investment assets are added together. Any unpaid expenses and other liabilities are subtracted from this total. The result is divided by the number of shares to determine the net asset value per share, which is calculated separately for each class of shares. (For funds with preferred shares, the amount subtracted from total assets includes the liquidation preference of preferred shares.)

**Statement of operations** shows the fund's net investment gain or loss. This is done by first adding up all the fund's earnings — from dividends and interest income — and subtracting its operating expenses to determine net investment income

(or loss). Then, any net gain or loss the fund realized on the sales of its holdings — as well as any unrealized gains or losses over the period — is added to or subtracted from the net investment result to determine the fund's net gain or loss for the fiscal period.

**Statement of changes in net assets** shows how the fund's net assets were affected by the fund's net investment gain or loss, by distributions to shareholders, and by changes in the number of the fund's shares. It lists distributions and their sources (net investment income or realized capital gains) over the current reporting period and the most recent fiscal year-end. The distributions listed here may not match the sources listed in the Statement of operations because the distributions are determined on a tax basis and may be paid in a different period from the one in which they were earned.

**Financial highlights** provide an overview of the fund's investment results, per-share distributions, expense ratios, net investment income ratios, and portfolio turnover (not required for money market funds) in one summary table, reflecting the five most recent reporting periods. In a semiannual report, the highlights table also includes the current reporting period.



## Report of Independent Registered Public Accounting Firm

To the Board of Trustees and Shareholders of  
Putnam Global Health Care Fund:

### ***Opinion on the Financial Statements***

We have audited the accompanying statement of assets and liabilities, including the fund's portfolio, of Putnam Global Health Care Fund (the "Fund") as of August 31, 2023, the related statement of operations for the year ended August 31, 2023, the statement of changes in net assets for each of the two years in the period ended August 31, 2023, including the related notes, and the financial highlights for each of the periods indicated therein (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Fund as of August 31, 2023, the results of its operations for the year then ended, the changes in its net assets for each of the two years in the period ended August 31, 2023 and the financial highlights for each of the periods indicated therein in conformity with accounting principles generally accepted in the United States of America.

### ***Basis for Opinion***

These financial statements are the responsibility of the Fund's management. Our responsibility is to express an opinion on the Fund's financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) ("PCAOB") and are required to be independent with respect to the Fund in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits of these financial statements in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. Our procedures included confirmation of securities owned as of August 31, 2023 by correspondence with the custodian, transfer agent and brokers; when replies were not received from brokers, we performed other auditing procedures. We believe that our audits provide a reasonable basis for our opinion.

PricewaterhouseCoopers LLP  
Boston, Massachusetts  
October 6, 2023

We have served as the auditor of one or more investment companies in the Putnam Investments family of funds since at least 1957. We have not been able to determine the specific year we began serving as auditor.

## The fund's portfolio 8/31/23

<b>COMMON STOCKS (93.9%)*</b>	<b>Shares</b>	<b>Value</b>
<b>Biotechnology (14.3%)</b>		
AbbVie, Inc.	529,100	\$77,756,536
Argenx SE (Netherlands) †	21,781	10,962,202
Ascendis Pharma A/SADR (Denmark) † S	545,356	53,455,795
Biogen, Inc. †	69,900	18,688,464
ImmunoGen, Inc. †	329,676	5,222,068
Regeneron Pharmaceuticals, Inc. †	51,900	42,894,844
Rocket Pharmaceuticals, Inc. †	569,300	8,909,545
Sarepta Therapeutics, Inc. †	31,200	3,775,512
		<b>221,664,966</b>
<b>Health care equipment and supplies (14.4%)</b>		
Boston Scientific Corp. †	1,159,500	62,543,430
Dexcom, Inc. †	585,500	59,123,790
Intuitive Surgical, Inc. †	266,200	83,235,416
Lantheus Holdings, Inc. †	172,400	11,799,056
Masimo Corp. †	9,500	1,085,660
Terumo Corp. (Japan)	141,900	4,290,807
		<b>222,078,159</b>
<b>Health care providers and services (18.1%)</b>		
Cigna Corp.	122,800	33,924,728
Humana, Inc.	72,800	33,606,664
McKesson Corp.	95,200	39,252,864
Option Care Health, Inc. †	1,126,500	39,235,995
UnitedHealth Group, Inc.	281,200	134,014,296
		<b>280,034,547</b>
<b>Life sciences tools and services (8.2%)</b>		
Danaher Corp.	119,200	31,588,000
IQVIA Holdings, Inc. †	110,300	24,556,089
Thermo Fisher Scientific, Inc.	125,500	69,916,050
		<b>126,060,139</b>
<b>Personal care products (0.9%)</b>		
Kenvue, Inc. †	600,269	13,836,200
		<b>13,836,200</b>
<b>Pharmaceuticals (38.0%)</b>		
4Front Ventures Corp. † Ω	49,896,829	6,336,897
AstraZeneca PLC (United Kingdom)	665,729	89,815,483
Curaleaf Holdings, Inc. † S	583,058	2,180,637
Daiichi Sankyo Co., Ltd. (Japan)	541,100	16,041,055
Eisai Co., Ltd. (Japan)	109,300	6,920,357
Eli Lilly and Co.	204,000	113,056,800
Green Thumb Industries, Inc. † S	284,400	2,659,140
Innoviva, Inc. † S Ω	5,157,531	65,758,520
Johnson & Johnson	246,943	39,925,744
Merck & Co., Inc.	531,538	57,927,011
Novo Nordisk A/S Class B (Denmark)	421,305	77,300,582
Sanofi (France)	745,667	79,347,641
Takeda Pharmaceutical Co., Ltd. (Japan)	603,800	18,682,644
TerrAscend Corp. (Canada) † S	5,980,632	12,260,296
		<b>588,212,807</b>
<b>Total common stocks (cost \$1,021,669,040)</b>		<b>\$1,451,886,818</b>

<b>U.S. TREASURY OBLIGATIONS (0.1%)*</b>	<b>Principal amount</b>	<b>Value</b>
U.S. Treasury Notes		
2.50%, 3/31/27 <sup>i</sup>	\$11,000	\$10,412
2.25%, 11/15/25 <sup>i</sup>	672,000	641,142
1.875%, 2/28/27 <sup>i</sup>	57,000	52,299
1.625%, 5/15/31 <sup>i</sup>	54,000	45,491
1.625%, 8/15/29 <sup>i</sup>	203,000	175,948
1.375%, 8/31/26 <sup>i</sup>	36,000	32,844
1.125%, 2/28/27 <sup>i</sup>	374,000	334,378
1.125%, 2/28/25 <sup>i</sup>	65,000	61,311
0.625%, 8/15/30 <sup>i</sup>	643,000	506,858
0.375%, 1/31/26 <sup>i</sup>	25,000	22,571
<b>Total U.S. treasury obligations (cost \$1,883,254)</b>		<b>\$1,883,254</b>

<b>SHORT-TERM INVESTMENTS (9.0%)*</b>		<b>Principal amount/ shares</b>	<b>Value</b>
Putnam Cash Collateral Pool, LLC 5.56% <sup>d</sup>	Shares	50,451,765	\$50,451,765
Putnam Short Term Investment Fund Class P 5.57% <sup>L</sup>	Shares	84,847,718	84,847,718
U.S. Treasury Bills 4.975%, 11/2/23 <sup>Δ</sup>		\$1,432,000	1,418,978
U.S. Treasury Bills 5.453%, 10/26/23 <sup>Δ</sup>		800,000	793,528
U.S. Treasury Bills 5.381%, 12/7/23 <sup>Δ</sup>		700,000	690,080
U.S. Treasury Bills 5.486%, 11/9/23 <sup>Δ</sup>		200,000	197,974
<b>Total short-term investments (cost \$138,401,496)</b>			<b>\$138,400,043</b>

<b>TOTAL INVESTMENTS</b>	
<b>Total investments (cost \$1,161,953,790)</b>	<b>\$1,592,170,115</b>

#### Key to holding's abbreviations

ADR American Depository Receipts: Represents ownership of foreign securities on deposit with a custodian bank.

#### Notes to the fund's portfolio

Unless noted otherwise, the notes to the fund's portfolio are for the close of the fund's reporting period, which ran from September 1, 2022 through August 31, 2023 (the reporting period). Within the following notes to the portfolio, references to "Putnam Management" represent Putnam Investment Management, LLC, the fund's manager, an indirect wholly-owned subsidiary of Putnam Investments, LLC and references to "ASC 820" represent Accounting Standards Codification 820 *Fair Value Measurements and Disclosures*.

\* Percentages indicated are based on net assets of \$1,545,890,055.

Ω Affiliated company (Note 5).

† This security is non-income-producing.

Δ This security, in part or in entirety, was pledged and segregated with the custodian for collateral on certain derivative contracts at the close of the reporting period. Collateral at period end totaled \$2,006,423 and is included in Investments in securities on the Statement of assets and liabilities (Notes 1 and 8).

<sup>d</sup> Affiliated company. See Notes 1 and 5 to the financial statements regarding securities lending. The rate quoted in the security description is the annualized 7-day yield of the fund at the close of the reporting period.

<sup>i</sup> This security was pledged, or purchased with cash that was pledged, to the fund for collateral on certain derivative contracts (Note 1).

<sup>L</sup> Affiliated company (Note 5). The rate quoted in the security description is the annualized 7-day yield of the fund at the close of the reporting period.

<sup>S</sup> Security on loan, in part or in entirety, at the close of the reporting period (Note 1).

Unless otherwise noted, the rates quoted in Short-term investments security descriptions represent the weighted average yield to maturity.

## DIVERSIFICATION BY COUNTRY △

Distribution of investments by country of risk at the close of the reporting period, excluding collateral received, if any (as a percentage of Portfolio Value):

United States	76.0%	Japan	3.0%
Denmark	8.5	Canada	0.8
United Kingdom	5.8	Netherlands	0.7
France	5.2	<b>Total</b>	<b>100.0%</b>

△ Methodology differs from that used for purposes of complying with the fund's policy regarding investments in securities of foreign issuers, as discussed further in the fund's prospectus.

## FORWARD CURRENCY CONTRACTS at 8/31/23 (aggregate face value \$276,732,647)

Counterparty	Currency	Contract type <sup>†</sup>	Delivery date	Value	Aggregate face value	Unrealized appreciation/ (depreciation)
<b>Bank of America N.A.</b>						
	Australian Dollar	Buy	10/18/23	\$46,012	\$47,188	\$(1,176)
	British Pound	Sell	9/20/23	4,671,786	4,566,023	(105,763)
	Swiss Franc	Buy	9/20/23	41,143,075	40,532,545	610,530
<b>Citibank, N.A.</b>						
	Danish Krone	Sell	9/20/23	32,716,898	32,608,356	(108,542)
<b>Goldman Sachs International</b>						
	British Pound	Sell	9/20/23	5,734,960	5,608,185	(126,775)
	Canadian Dollar	Sell	10/18/23	1,801,959	1,835,728	33,769
	Japanese Yen	Buy	11/15/23	16,534,745	16,902,980	(368,235)
<b>HSBC Bank USA, National Association</b>						
	British Pound	Sell	9/20/23	7,669,756	7,497,062	(172,694)
	Canadian Dollar	Sell	10/18/23	2,610,070	2,658,801	48,731
	Danish Krone	Sell	9/20/23	6,010,626	5,984,886	(25,740)
	Swiss Franc	Buy	9/20/23	41,319,166	40,656,019	663,147
<b>JPMorgan Chase Bank N.A.</b>						
	British Pound	Sell	9/20/23	3,302,531	3,223,017	(79,514)
	Canadian Dollar	Sell	10/18/23	4,875,330	4,974,682	99,352
	Euro	Sell	9/20/23	2,011,168	2,009,543	(1,625)
	Japanese Yen	Buy	11/15/23	4,198,902	4,292,688	(93,786)
<b>Morgan Stanley &amp; Co. International PLC</b>						
	Australian Dollar	Buy	10/18/23	2,548,948	2,614,093	(65,145)
	British Pound	Sell	9/20/23	6,533,228	6,397,958	(135,270)
	Euro	Sell	9/20/23	3,193,085	3,190,220	(2,865)
	Swiss Franc	Buy	9/20/23	10,400,233	10,255,255	144,978
<b>NatWest Markets PLC</b>						
	Australian Dollar	Buy	10/18/23	22,906,848	23,492,008	(585,160)
	Danish Krone	Sell	9/20/23	10,360,259	10,329,807	(30,452)
<b>State Street Bank and Trust Co.</b>						
	Canadian Dollar	Sell	10/18/23	1,311,552	1,336,201	24,649
	Danish Krone	Sell	9/20/23	8,410,354	8,574,804	164,450
	Swiss Franc	Buy	9/20/23	19,894,049	19,620,148	273,901

**FORWARD CURRENCY CONTRACTS at 8/31/23 (aggregate face value \$276,732,647) cont.**

Counterparty	Currency	Contract type*	Delivery date	Value	Aggregate face value	Unrealized appreciation/(depreciation)
<b>UBSAG</b>						
	Danish Krone	Sell	9/20/23	\$8,370,367	\$8,151,332	\$(219,035)
	Japanese Yen	Buy	11/15/23	919,812	939,846	(20,034)
	Swiss Franc	Buy	9/20/23	1,467,233	1,446,673	20,560
<b>WestPac Banking Corp.</b>						
	Euro	Buy	9/20/23	6,855,051	6,986,599	(131,548)
<b>Unrealized appreciation</b>						<b>2,084,067</b>
<b>Unrealized (depreciation)</b>						<b>(2,273,359)</b>
<b>Total</b>						<b>\$(189,292)</b>

\* The exchange currency for all contracts listed is the United States Dollar.

ASC 820 establishes a three-level hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of the fund's investments. The three levels are defined as follows:

Level 1: Valuations based on quoted prices for identical securities in active markets.

Level 2: Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.

Level 3: Valuations based on inputs that are unobservable and significant to the fair value measurement.

The following is a summary of the inputs used to value the fund's net assets as of the close of the reporting period:

Investments in securities:	Valuation inputs		
	Level 1	Level 2	Level 3
Common stocks*:			
Consumer staples	\$13,836,200	\$—	\$—
Health care	1,134,689,847	303,360,771	—
<b>Total common stocks</b>	<b>1,148,526,047</b>	<b>303,360,771</b>	<b>—</b>
U.S. treasury obligations	—	1,883,254	—
Short-term investments	—	138,400,043	—
<b>Totals by level</b>	<b>\$1,148,526,047</b>	<b>\$443,644,068</b>	<b>\$—</b>

Other financial instruments:	Valuation inputs		
	Level 1	Level 2	Level 3
Forward currency contracts	\$—	\$(189,292)	\$—
<b>Totals by level</b>	<b>\$—</b>	<b>\$(189,292)</b>	<b>\$—</b>

\* Common stock classifications are presented at the sector level, which may differ from the fund's portfolio presentation.

The accompanying notes are an integral part of these financial statements.

## Statement of assets and liabilities 8/31/23

### ASSETS

Investment in securities, at value, including \$50,167,760 of securities on loan (Notes 1 and 8):	
Unaffiliated issuers (identified cost \$916,821,086)	\$1,384,775,215
Affiliated issuers (identified cost \$245,132,704) (Note 5)	207,394,900
Dividends, interest and other receivables	2,014,460
Foreign tax reclaim	2,104,223
Receivable for shares of the fund sold	637,453
Receivable for investments sold	21,063,766
Unrealized appreciation on forward currency contracts (Note 1)	2,084,067
Prepaid assets	49,393
<b>Total assets</b>	<b>1,620,123,477</b>

### LIABILITIES

Payable for investments purchased	16,448,727
Payable for shares of the fund repurchased	892,158
Payable for compensation of Manager (Note 2)	813,763
Payable for custodian fees (Note 2)	19,867
Payable for investor servicing fees (Note 2)	362,730
Payable for Trustee compensation and expenses (Note 2)	341,681
Payable for administrative services (Note 2)	5,252
Payable for distribution fees (Note 2)	589,787
Unrealized depreciation on forward currency contracts (Note 1)	2,273,359
Collateral on securities loaned, at value (Note 1)	50,451,765
Collateral on certain derivative contracts, at value (Notes 1 and 8)	1,883,264
Other accrued expenses	151,069
<b>Total liabilities</b>	<b>74,233,422</b>
<b>Net assets</b>	<b>\$1,545,890,055</b>

### REPRESENTED BY

Paid-in capital (Unlimited shares authorized) (Notes 1 and 4)	\$1,042,259,978
Total distributable earnings (Note 1)	503,630,077
<b>Total — Representing net assets applicable to capital shares outstanding</b>	<b>\$1,545,890,055</b>

(Continued on next page)

## Statement of assets and liabilities *cont.*

### COMPUTATION OF NET ASSET VALUE AND OFFERING PRICE

Net asset value and redemption price per class A share (\$1,341,541,428 divided by 23,360,824 shares)	\$57.43
Offering price per class A share (100/94.25 of \$57.43)*	\$60.93
Net asset value and offering price per class B share (\$4,223,996 divided by 196,249 shares)**	\$21.52
Net asset value and offering price per class C share (\$17,384,820 divided by 502,120 shares)**	\$34.62
Net asset value, offering price and redemption price per class R share (\$1,783,148 divided by 34,559 shares)	\$51.60
Net asset value, offering price and redemption price per class R6 share (\$28,923,740 divided by 451,724 shares)	\$64.03
Net asset value, offering price and redemption price per class Y share (\$152,032,923 divided by 2,381,378 shares)	\$63.84

\*On single retail sales of less than \$50,000. On sales of \$50,000 or more the offering price is reduced.

\*\*Redemption price per share is equal to net asset value less any applicable contingent deferred sales charge.

The accompanying notes are an integral part of these financial statements.

## Statement of operations Year ended 8/31/23

<b>INVESTMENT INCOME</b>	
Dividends (net of foreign tax of \$813,468)	\$17,633,141
Interest (including interest income of \$2,585,333 from investments in affiliated issuers) (Note 5)	2,711,930
Securities lending (net of expenses) (Notes 1 and 5)	195,900
<b>Total investment income</b>	<b>20,540,971</b>
<b>EXPENSES</b>	
Compensation of Manager (Note 2)	9,594,239
Investor servicing fees (Note 2)	2,225,078
Custodian fees (Note 2)	97,218
Trustee compensation and expenses (Note 2)	67,804
Distribution fees (Note 2)	3,599,657
Administrative services (Note 2)	50,345
Other	551,281
<b>Total expenses</b>	<b>16,185,622</b>
Expense reduction (Note 2)	(20,088)
<b>Net expenses</b>	<b>16,165,534</b>
<b>Net investment income</b>	<b>4,375,437</b>
<b>REALIZED AND UNREALIZED GAIN (LOSS)</b>	
<b>Net realized gain (loss) on:</b>	
Securities from unaffiliated issuers (Notes 1 and 3)	76,198,479
Securities from affiliated issuers (Note 5)	(836,788)
Foreign currency transactions (Note 1)	(15,924)
Forward currency contracts (Note 1)	3,498,757
<b>Total net realized gain</b>	<b>78,844,524</b>
<b>Change in net unrealized appreciation (depreciation) on:</b>	
Securities from unaffiliated issuers	114,576,941
Securities from affiliated issuers (Note 5)	(20,922,239)
Assets and liabilities in foreign currencies	203,318
Forward currency contracts	(4,832,167)
<b>Total change in net unrealized appreciation</b>	<b>89,025,853</b>
<b>Net gain on investments</b>	<b>167,870,377</b>
<b>Net increase in net assets resulting from operations</b>	<b>\$172,245,814</b>

The accompanying notes are an integral part of these financial statements.



## Statement of changes in net assets

INCREASE (DECREASE) IN NET ASSETS	Year ended 8/31/23	Year ended 8/31/22
<b>Operations</b>		
Net investment income	\$4,375,437	\$4,702,660
Net realized gain on investments and foreign currency transactions	78,844,524	110,698,062
Change in net unrealized appreciation (depreciation) of investments and assets and liabilities in foreign currencies	89,025,853	(266,449,071)
<b>Net increase (decrease) in net assets resulting from operations</b>	<b>172,245,814</b>	<b>(151,048,349)</b>
Distributions to shareholders (Note 1):		
From ordinary income		
Net investment income		
Class A	(1,851,737)	(7,778,303)
Class B	—	(63,412)
Class C	—	(48,478)
Class R	—	(3,862)
Class R6	(125,432)	(148,266)
Class Y	(599,328)	(813,870)
Net realized short-term gain on investments		
Class A	—	(65,913,785)
Class B	—	(1,033,361)
Class C	—	(1,757,319)
Class R	—	(79,158)
Class R6	—	(774,197)
Class Y	—	(4,741,708)
From capital gain on investments		
Net realized long-term gain on investments		
Class A	(100,107,724)	(92,179,412)
Class B	(1,252,749)	(1,445,139)
Class C	(2,492,163)	(2,457,583)
Class R	(146,942)	(110,701)
Class R6	(1,947,754)	(1,082,702)
Class Y	(10,980,992)	(6,631,205)
Increase (decrease) from capital share transactions (Note 4)	(6,095,274)	136,448,285
<b>Total increase (decrease) in net assets</b>	<b>46,645,719</b>	<b>(201,662,525)</b>
<b>NET ASSETS</b>		
Beginning of year	1,499,244,336	1,700,906,861
<b>End of year</b>	<b>\$1,545,890,055</b>	<b>\$1,499,244,336</b>

The accompanying notes are an integral part of these financial statements.

## Financial highlights

(For a common share outstanding throughout the period)

Period ended	INVESTMENT OPERATIONS			LESS DISTRIBUTIONS	
	Net asset value, beginning of period	Net investment income (loss) <sup>a</sup>	Net realized and unrealized gain (loss) on investments	Total from investment operations	From net investment income
<b>Class A</b>					
August 31, 2023	<b>\$55.47</b>	.15	6.27	<b>6.42</b>	(.08)
August 31, 2022	<b>68.43</b>	.17	(5.53)	<b>(5.36)</b>	(.36)
August 31, 2021	<b>60.86</b>	.34	12.94	<b>13.28</b>	(.51)
August 31, 2020	<b>50.99</b>	.41	12.69	<b>13.10</b>	(.17)
August 31, 2019	<b>54.00</b>	.29	(.18)	<b>.11</b>	(.03)
<b>Class B</b>					
August 31, 2023	<b>\$23.43</b>	(.11)	2.58	<b>2.47</b>	—
August 31, 2022	<b>33.22</b>	(.13)	(2.23)	<b>(2.36)</b>	(.19)
August 31, 2021	<b>32.37</b>	(.07)	6.44	<b>6.37</b>	(.32)
August 31, 2020	<b>28.45</b>	— <sup>e</sup>	6.98	<b>6.98</b>	—
August 31, 2019	<b>31.90</b>	(.05)	(.31)	<b>(.36)</b>	—
<b>Class C</b>					
August 31, 2023	<b>\$35.23</b>	(.17)	3.94	<b>3.77</b>	—
August 31, 2022	<b>46.21</b>	(.19)	(3.47)	<b>(3.66)</b>	(.08)
August 31, 2021	<b>42.91</b>	(.09)	8.84	<b>8.75</b>	(.25)
August 31, 2020	<b>36.87</b>	— <sup>e</sup>	9.10	<b>9.10</b>	—
August 31, 2019	<b>40.29</b>	(.07)	(.26)	<b>(.33)</b>	—
<b>Class R</b>					
August 31, 2023	<b>\$50.30</b>	.02	5.66	<b>5.68</b>	—
August 31, 2022	<b>62.68</b>	.03	(5.02)	<b>(4.99)</b>	(.15)
August 31, 2021	<b>56.13</b>	.17	11.88	<b>12.05</b>	(.30)
August 31, 2020	<b>47.27</b>	.26	11.73	<b>11.99</b>	(.07)
August 31, 2019	<b>50.40</b>	.15	(.19)	<b>(.04)</b>	—
<b>Class R6</b>					
August 31, 2023	<b>\$61.35</b>	.38	6.96	<b>7.34</b>	(.28)
August 31, 2022	<b>74.89</b>	.49	(6.21)	<b>(5.72)</b>	(.58)
August 31, 2021	<b>65.97</b>	.61	14.11	<b>14.72</b>	(.60)
August 31, 2020 <sup>†</sup>	<b>62.85</b>	.17	2.95	<b>3.12</b>	—
<b>Class Y</b>					
August 31, 2023	<b>\$61.20</b>	.32	6.94	<b>7.26</b>	(.24)
August 31, 2022	<b>74.73</b>	.36	(6.13)	<b>(5.77)</b>	(.52)
August 31, 2021	<b>65.94</b>	.54	14.10	<b>14.64</b>	(.65)
August 31, 2020	<b>54.99</b>	.56	13.75	<b>14.31</b>	(.30)
August 31, 2019	<b>57.97</b>	.44	(.16)	<b>.28</b>	(.17)

\* Not annualized.

† For the period June 1, 2020 (commencement of operations) to August 31, 2020.

<sup>a</sup> Per share net investment income (loss) has been determined on the basis of the weighted average number of shares outstanding during the period.

<sup>b</sup> Total return assumes dividend reinvestment and does not reflect the effect of sales charges.

				RATIOS AND SUPPLEMENTAL DATA			
From net realized gain on investments	Total distributions	Net asset value, end of period	Total return at net asset value (%) <sup>b</sup>	Net assets, end of period (in thousands)	Ratio of expenses to average net assets (%) <sup>c</sup>	Ratio of net investment income (loss) to average net assets (%)	Portfolio turnover (%)
(4.38)	(4.46)	\$57.43	11.79	\$1,341,541	1.07	.27	41
(7.24)	(7.60)	55.47	(9.11)	1,292,980	1.05	.28	71
(5.20)	(5.71)	68.43	23.43	1,522,142	1.05	.55	61
(3.06)	(3.23)	60.86	26.16	1,324,490	1.07	.75	82
(3.09)	(3.12)	50.99	1.15	1,133,447	1.09	.57	81
(4.38)	(4.38)	\$21.52	10.94	\$4,224	1.82	(.51)	41
(7.24)	(7.43)	23.43	(9.79)	7,845	1.80	(.48)	71
(5.20)	(5.52)	33.22	22.50	13,072	1.80	(.21)	61
(3.06)	(3.06)	32.37	25.27	15,467	1.82	— <sup>d</sup>	82
(3.09)	(3.09)	28.45	.39	17,141	1.84	(.18)	81
(4.38)	(4.38)	\$34.62	10.96	\$17,385	1.82	(.50)	41
(7.24)	(7.32)	35.23	(9.81)	21,218	1.80	(.47)	71
(5.20)	(5.45)	46.21	22.49	29,722	1.80	(.20)	61
(3.06)	(3.06)	42.91	25.25	33,172	1.82	(.01)	82
(3.09)	(3.09)	36.87	.38	29,905	1.84	(.18)	81
(4.38)	(4.38)	\$51.60	11.51	\$1,783	1.32	.05	41
(7.24)	(7.39)	50.30	(9.34)	1,603	1.30	.05	71
(5.20)	(5.50)	62.68	23.13	2,029	1.30	.29	61
(3.06)	(3.13)	56.13	25.85	2,272	1.32	.52	82
(3.09)	(3.09)	47.27	.91	2,252	1.34	.32	81
(4.38)	(4.66)	\$64.03	12.19	\$28,924	.72	.61	41
(7.24)	(7.82)	61.35	(8.82)	29,327	.71	.74	71
(5.20)	(5.80)	74.89	23.86	19,470	.71	.89	61
—	—	65.97	4.96 <sup>e</sup>	16,348	.18 <sup>e</sup>	.26 <sup>e</sup>	82
(4.38)	(4.62)	\$63.84	12.07	\$152,033	.82	.51	41
(7.24)	(7.76)	61.20	(8.90)	146,272	.80	.53	71
(5.20)	(5.85)	74.73	23.74	114,471	.80	.80	61
(3.06)	(3.36)	65.94	26.49	92,183	.82	.93	82
(3.09)	(3.26)	54.99	1.41	64,674	.84	.82	81

<sup>c</sup>Includes amounts paid through expense offset and brokerage service arrangements, if any (Note 2). Also excludes acquired fund fees and expenses, if any.

<sup>d</sup>Represents less than 0.01% of average net assets.

<sup>e</sup>Represents less than \$0.01 per share.

The accompanying notes are an integral part of these financial statements.

## Notes to financial statements 8/31/23

Unless otherwise noted, the “reporting period” represents the period from September 1, 2022 through August 31, 2023. The following table defines commonly used references within the Notes to financial statements:

References to	Represent
Putnam Management	Putnam Investment Management, LLC, the fund’s manager, an indirect wholly-owned subsidiary of Putnam Investments, LLC
State Street	State Street Bank and Trust Company
JPMorgan	JPMorgan Chase Bank, N.A.
the SEC	the Securities and Exchange Commission
OTC	over-the-counter
PAC	The Putnam Advisory Company, LLC, an affiliate of Putnam Management
PIL	Putnam Investments Limited, an affiliate of Putnam Management

Putnam Global Health Care Fund (the fund) is a Massachusetts business trust, which is registered under the Investment Company Act of 1940, as amended, as a non-diversified open-end management investment company. The goal of the fund is to seek capital appreciation. For this non-diversified fund concentrating in the health care industries, the fund invests mainly in common stocks (growth or value stocks or both) of large and midsize companies worldwide that Putnam Management believes have favorable investment potential. Under normal circumstances, the fund invests at least 80% of the fund’s net assets in securities of companies in the health care industries. This policy may be changed only after 60 days’ notice to shareholders. Potential investments include companies that manufacture health care supplies or provide health care-related services, and companies in the research, development, production and marketing of pharmaceuticals and biotechnology products. The fund may purchase stocks of companies with stock prices that reflect a value lower than that which Putnam Management places on the company. Putnam Management may consider, among other factors, a company’s valuation, financial strength, growth potential, competitive position in its industry, projected future earnings, cash flows and dividends when deciding whether to buy or sell investments. Putnam Management may also consider other factors that Putnam Management believes will cause the stock price to rise. The fund may also use derivatives, such as futures, options, certain foreign currency transactions, warrants and swap contracts, for both hedging and non-hedging purposes, and may engage in short sales of securities. For example, the fund typically uses foreign currency forward contracts in connection with the fund’s investments in foreign securities in order to hedge the fund’s currency exposure relative to the fund’s benchmark index. The use of the term “global” in the fund’s name is meant to emphasize that Putnam Management looks for investment opportunities on a worldwide basis and that its investment strategies are not constrained by the countries or regions in which companies are located. Under normal market conditions, the fund intends to invest in at least five different countries and at least 40% of its net assets in securities of foreign companies (or, if less, at least the percentage of net assets that is ten percentage points less than the percentage of the fund’s benchmark represented by foreign companies, as determined by the providers of the benchmark).

The fund offers the following share classes. The expenses for each class of shares may differ based on the distribution and investor servicing fees of each class, which are identified in Note 2.

Share class	Sales charge	Contingent deferred sales charge	Conversion feature
Class A	Up to 5.75%	1.00% on certain redemptions of shares bought with no initial sales charge	None
Class B*	None	5.00% phased out over six years	Converts to class A shares after 8 years
Class C	None	1.00% eliminated after one year	Converts to class A shares after 8 years
Class R	None	None	None
Class R6†	None	None	None
Class Y†	None	None	None

\* Purchases of class B shares are closed to new and existing investors except by exchange from class B shares of another Putnam fund or through dividend and/or capital gains reinvestment.

† Not available to all investors.

In the normal course of business, the fund enters into contracts that may include agreements to indemnify another party under given circumstances. The fund's maximum exposure under these arrangements is unknown as this would involve future claims that may be, but have not yet been, made against the fund. However, the fund's management team expects the risk of material loss to be remote.

The fund has entered into contractual arrangements with an investment adviser, administrator, distributor, shareholder servicing agent and custodian, who each provide services to the fund. Unless expressly stated otherwise, shareholders are not parties to, or intended beneficiaries of these contractual arrangements, and these contractual arrangements are not intended to create any shareholder right to enforce them against the service providers or to seek any remedy under them against the service providers, either directly or on behalf of the fund.

Under the fund's Amended and Restated Agreement and Declaration of Trust, any claims asserted by a shareholder against or on behalf of the fund, including claims against Trustees and Officers, must be brought in state and federal courts located within the Commonwealth of Massachusetts.

### **Note 1: Significant accounting policies**

The following is a summary of significant accounting policies consistently followed by the fund in the preparation of its financial statements. The preparation of financial statements is in conformity with accounting principles generally accepted in the United States of America and requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities in the financial statements and the reported amounts of increases and decreases in net assets from operations. Actual results could differ from those estimates. Subsequent events after the Statement of assets and liabilities date through the date that the financial statements were issued have been evaluated in the preparation of the financial statements.

Investment income, realized and unrealized gains and losses and expenses of the fund are borne pro-rata based on the relative net assets of each class to the total net assets of the fund, except that each class bears expenses unique to that class (including the distribution fees applicable to such classes). Each class votes as a class only with respect to its own distribution plan or other matters on which a class vote is required by law or determined by the Trustees. If the fund were liquidated, shares of each class would receive their pro-rata share of the net assets of the fund. In addition, the Trustees declare separate dividends on each class of shares.

**Security valuation** Portfolio securities and other investments are valued using policies and procedures adopted by the Board of Trustees. The Trustees have formed a Pricing Committee to oversee the implementation of these procedures and have delegated responsibility for valuing the fund's assets in accordance with these procedures to Putnam Management. Putnam Management has established an internal Valuation Committee that is responsible for making fair value determinations, evaluating the effectiveness of the pricing policies of the fund and reporting to the Pricing Committee.

Investments for which market quotations are readily available are valued at the last reported sales price on their principal exchange, or official closing price for certain markets, and are classified as Level 1 securities under Accounting Standards Codification 820 *Fair Value Measurements and Disclosures* (ASC 820). If no sales are reported, as in the case of some securities that are traded OTC, a security is valued at its last reported bid price and is generally categorized as a Level 2 security.

Investments in open-end investment companies (excluding exchange-traded funds), if any, which can be classified as Level 1 or Level 2 securities, are valued based on their net asset value. The net asset value of such investment companies equals the total value of their assets less their liabilities and divided by the number of their outstanding shares.

Market quotations are not considered to be readily available for certain debt obligations (including short-term investments with remaining maturities of 60 days or less) and other investments; such investments are valued on the basis of valuations furnished by an independent pricing service approved by the Trustees or dealers selected by Putnam Management. Such services or dealers determine valuations for normal institutional-size trading units of such securities using methods based on market transactions for comparable securities and various relationships, generally recognized by institutional traders, between securities (which consider such factors as security prices, yields, maturities and ratings). These securities will generally be categorized as Level 2.

Many securities markets and exchanges outside the U.S. close prior to the scheduled close of the New York Stock Exchange and therefore the closing prices for securities in such markets or on such exchanges may not fully reflect events that occur after such close but before the scheduled close of the New York Stock Exchange. Accordingly, on certain days, the fund will fair value certain foreign equity securities taking into account multiple factors including movements in the U.S. securities markets, currency valuations and comparisons to the valuation of

American Depositary Receipts, exchange-traded funds and futures contracts. The foreign equity securities, which would generally be classified as Level 1 securities, will be transferred to Level 2 of the fair value hierarchy when they are valued at fair value. The number of days on which fair value prices will be used will depend on market activity and it is possible that fair value prices will be used by the fund to a significant extent. At the close of the reporting period, fair value pricing was used for certain foreign securities in the portfolio. Securities quoted in foreign currencies, if any, are translated into U.S. dollars at the current exchange rate.

To the extent a pricing service or dealer is unable to value a security or provides a valuation that Putnam Management does not believe accurately reflects the security's fair value, the security will be valued at fair value by Putnam Management, which has been designated as valuation designee pursuant to Rule 2a-5 under the Investment Company Act of 1940, in accordance with policies and procedures approved by the Trustees. Certain investments, including certain restricted and illiquid securities and derivatives, are also valued at fair value following procedures approved by the Trustees. These valuations consider such factors as significant market or specific security events such as interest rate or credit quality changes, various relationships with other securities, discount rates, U.S. Treasury, U.S. swap and credit yields, index levels, convexity exposures, recovery rates, sales and other multiples and resale restrictions. These securities are classified as Level 2 or as Level 3 depending on the priority of the significant inputs.

To assess the continuing appropriateness of fair valuations, the Valuation Committee reviews and affirms the reasonableness of such valuations on a regular basis after considering all relevant information that is reasonably available. Such valuations and procedures are reviewed periodically by the Trustees. The fair value of securities is generally determined as the amount that the fund could reasonably expect to realize from an orderly disposition of such securities over a reasonable period of time. By its nature, a fair value price is a good faith estimate of the value of a security in a current sale and does not reflect an actual market price, which may be different by a material amount.

**Security transactions and related investment income** Security transactions are recorded on the trade date (the date the order to buy or sell is executed). Gains or losses on securities sold are determined on the identified cost basis.

Interest income, net of any applicable withholding taxes, if any, is recorded on the accrual basis. Amortization and accretion of premiums and discounts on debt securities, if any, is recorded on the accrual basis.

Dividend income, net of any applicable withholding taxes, is recognized on the ex-dividend date except that certain dividends from foreign securities, if any, are recognized as soon as the fund is informed of the ex-dividend date. Non-cash dividends, if any, are recorded at the fair value of the securities received. Dividends representing a return of capital or capital gains, if any, are reflected as a reduction of cost and/or as a realized gain.

**Foreign currency translation** The accounting records of the fund are maintained in U.S. dollars. The fair value of foreign securities, currency holdings, and other assets and liabilities is recorded in the books and records of the fund after translation to U.S. dollars based on the exchange rates on that day. The cost of each security is determined using historical exchange rates. Income and withholding taxes are translated at prevailing exchange rates when earned or incurred. The fund does not isolate that portion of realized or unrealized gains or losses resulting from changes in the foreign exchange rate on investments from fluctuations arising from changes in the market prices of the securities. Such gains and losses are included with the net realized and unrealized gain or loss on investments. Net realized gains and losses on foreign currency transactions represent net realized exchange gains or losses on disposition of foreign currencies, currency gains and losses realized between the trade and settlement dates on securities transactions and the difference between the amount of investment income and foreign withholding taxes recorded on the fund's books and the U.S. dollar equivalent amounts actually received or paid. Net unrealized appreciation and depreciation of assets and liabilities in foreign currencies arise from changes in the value of assets and liabilities other than investments at the period end, resulting from changes in the exchange rate.

**Forward currency contracts** The fund buys and sells forward currency contracts, which are agreements between two parties to buy and sell currencies at a set price on a future date. These contracts are used to hedge foreign exchange risk.

The U.S. dollar value of forward currency contracts is determined using current forward currency exchange rates supplied by a quotation service. The fair value of the contract will fluctuate with changes in currency exchange rates. The contract is marked to market daily and the change in fair value is recorded as an unrealized gain or loss. The fund records a realized gain or loss equal to the difference between the value of the contract at the time it was opened and the value at the time it was closed when the contract matures or by delivery of the currency. The fund

could be exposed to risk if the value of the currency changes unfavorably, if the counterparties to the contracts are unable to meet the terms of their contracts or if the fund is unable to enter into a closing position. Risks may exceed amounts recognized on the Statement of assets and liabilities.

Forward currency contracts outstanding at period end, if any, are listed after the fund's portfolio.

**Master agreements** The fund is a party to ISDA (International Swaps and Derivatives Association, Inc.) Master Agreements (Master Agreements) with certain counterparties that govern OTC derivative and foreign exchange contracts entered into from time to time. The Master Agreements may contain provisions regarding, among other things, the parties' general obligations, representations, agreements, collateral requirements, events of default and early termination. With respect to certain counterparties, in accordance with the terms of the Master Agreements, collateral pledged to the fund is held in a segregated account by the fund's custodian and, with respect to those amounts which can be sold or repledged, is presented in the fund's portfolio.

Collateral pledged by the fund is segregated by the fund's custodian and identified in the fund's portfolio. Collateral can be in the form of cash or debt securities issued by the U.S. Government or related agencies or other securities as agreed to by the fund and the applicable counterparty. Collateral requirements are determined based on the fund's net position with each counterparty.

Termination events applicable to the fund may occur upon a decline in the fund's net assets below a specified threshold over a certain period of time. Termination events applicable to counterparties may occur upon a decline in the counterparty's long-term and short-term credit ratings below a specified level. In each case, upon occurrence, the other party may elect to terminate early and cause settlement of all derivative and foreign exchange contracts outstanding, including the payment of any losses and costs resulting from such early termination, as reasonably determined by the terminating party. Any decision by one or more of the fund's counterparties to elect early termination could impact the fund's future derivative activity.

At the close of the reporting period, the fund had a net liability position of \$1,669,327 on open derivative contracts subject to the Master Agreements. Collateral pledged by the fund at period end for these agreements totaled \$2,006,423 and may include amounts related to unsettled agreements.

**Securities lending** The fund may lend securities, through its agent, to qualified borrowers in order to earn additional income. The loans are collateralized by cash in an amount at least equal to the fair value of the securities loaned. The fair value of securities loaned is determined daily and any additional required collateral is allocated to the fund on the next business day. The remaining maturities of the securities lending transactions are considered overnight and continuous. The risk of borrower default will be borne by the fund's agent; the fund will bear the risk of loss with respect to the investment of the cash collateral. Income from securities lending, net of expenses, is included in investment income on the Statement of operations. Cash collateral is invested in Putnam Cash Collateral Pool, LLC, a limited liability company managed by an affiliate of Putnam Management. Investments in Putnam Cash Collateral Pool, LLC are valued at its closing net asset value each business day. There are no management fees charged to Putnam Cash Collateral Pool, LLC. At the close of the reporting period, the fund received cash collateral of \$50,451,765 and the value of securities loaned amounted to \$50,167,760.

**Interfund lending** The fund, along with other Putnam funds, may participate in an interfund lending program pursuant to an exemptive order issued by the SEC. This program allows the fund to borrow from or lend to other Putnam funds that permit such transactions. Interfund lending transactions are subject to each fund's investment policies and borrowing and lending limits. Interest earned or paid on the interfund lending transaction will be based on the average of certain current market rates. During the reporting period, the fund did not utilize the program.

**Lines of credit** The fund participates, along with other Putnam funds, in a \$320 million syndicated unsecured committed line of credit, provided by State Street (\$160 million) and JPMorgan (\$160 million), and a \$235.5 million unsecured uncommitted line of credit, provided by State Street. Prior to May 2, 2023, the fund participated, along with other Putnam funds, in a \$100 million unsecured committed line of credit and a \$235.5 million unsecured uncommitted line of credit, both provided by State Street. Borrowings may be made for temporary or emergency purposes, including the funding of shareholder redemption requests and trade settlements. Interest is charged to the fund based on the fund's borrowing at a rate equal to 1.25% plus the higher of (1) the Federal Funds rate and (2) the Overnight Bank Funding Rate for the committed line of credit and 1.30% plus the higher of (1) the Federal Funds rate and (2) the Overnight Bank Funding Rate for the uncommitted line of credit. A closing fee equal to 0.04% of the committed line of credit and 0.04% of the uncommitted line of credit has been paid by the participating funds and a \$75,000 fee has been paid by the participating funds to State Street as agent of the syndicated committed line of credit. In addition, a commitment fee of 0.21% per annum on any unutilized portion

of the committed line of credit is allocated to the participating funds based on their relative net assets and paid quarterly. During the reporting period, the fund had no borrowings against these arrangements.

**Federal taxes** It is the policy of the fund to distribute all of its taxable income within the prescribed time period and otherwise comply with the provisions of the Internal Revenue Code of 1986, as amended (the Code), applicable to regulated investment companies. It is also the intention of the fund to distribute an amount sufficient to avoid imposition of any excise tax under Section 4982 of the Code.

The fund is subject to the provisions of Accounting Standards Codification 740 *Income Taxes* (ASC 740). ASC 740 sets forth a minimum threshold for financial statement recognition of the benefit of a tax position taken or expected to be taken in a tax return. The fund did not have a liability to record for any unrecognized tax benefits in the accompanying financial statements. No provision has been made for federal taxes on income, capital gains or unrealized appreciation on securities held nor for excise tax on income and capital gains. Each of the fund's federal tax returns for the prior three fiscal years remains subject to examination by the Internal Revenue Service.

The fund may also be subject to taxes imposed by governments of countries in which it invests. Such taxes are generally based on either income or gains earned or repatriated. The fund accrues and applies such taxes to net investment income, net realized gains and net unrealized gains as income and/or capital gains are earned. In some cases, the fund may be entitled to reclaim all or a portion of such taxes, and such reclaim amounts, if any, are reflected as an asset on the fund's books. In many cases, however, the fund may not receive such amounts for an extended period of time, depending on the country of investment.

**Distributions to shareholders** Distributions to shareholders from net investment income, if any, are recorded by the fund on the ex-dividend date. Distributions from capital gains, if any, are recorded on the ex-dividend date and paid at least annually. The amount and character of income and gains to be distributed are determined in accordance with income tax regulations, which may differ from generally accepted accounting principles. These differences include temporary and/or permanent differences from losses on wash sale transactions and from foreign currency gains and losses. Reclassifications are made to the fund's capital accounts to reflect income and gains available for distribution (or available capital loss carryovers) under income tax regulations. At the close of the reporting period, the fund reclassified \$3,483,683 to increase undistributed net investment income and \$3,483,683 to decrease accumulated net realized gain.

Tax cost of investments includes adjustments to net unrealized appreciation (depreciation) which may not necessarily be final tax cost basis adjustments, but closely approximate the tax basis unrealized gains and losses that may be realized and distributed to shareholders. The tax basis components of distributable earnings and the federal tax cost as of the close of the reporting period were as follows:

Unrealized appreciation	\$504,488,409
Unrealized depreciation	(81,745,879)
Net unrealized appreciation	422,742,530
Undistributed ordinary income	2,985,722
Undistributed long-term gains	77,885,292
Cost for federal income tax purposes	\$1,169,238,293

**Note 2: Management fee, administrative services and other transactions**

The fund pays Putnam Management a management fee (based on the fund's average net assets and computed and paid monthly) at annual rates that may vary based on the average of the aggregate net assets of all open-end mutual funds sponsored by Putnam Management (excluding net assets of funds that are invested in, or that are invested in by, other Putnam funds to the extent necessary to avoid "double counting" of those assets). Such annual rates may vary as follows:

0.780%	of the first \$5 billion,	0.580%	of the next \$50 billion,
0.730%	of the next \$5 billion,	0.560%	of the next \$50 billion,
0.680%	of the next \$10 billion,	0.550%	of the next \$100 billion and
0.630%	of the next \$10 billion,	0.545%	of any excess thereafter.

For the reporting period, the management fee represented an effective rate (excluding the impact from any expense waivers in effect) of 0.621% of the fund's average net assets.



Putnam Management has contractually agreed, through December 30, 2024, to waive fees and/or reimburse the fund's expenses to the extent necessary to limit the cumulative expenses of the fund, exclusive of brokerage, interest, taxes, investment-related expenses, extraordinary expenses, acquired fund fees and expenses and payments under the fund's investor servicing contract, investment management contract and distribution plans, on a fiscal year-to-date basis to an annual rate of 0.20% of the fund's average net assets over such fiscal year-to-date period. During the reporting period, the fund's expenses were not reduced as a result of this limit.

PIL is authorized by the Trustees to manage a separate portion of the assets of the fund as determined by Putnam Management from time to time. PIL did not manage any portion of the assets of the fund during the reporting period. If Putnam Management were to engage the services of PIL, Putnam Management would pay a quarterly sub-management fee to PIL for its services at an annual rate of 0.25% of the average net assets of the portion of the fund managed by PIL.

PAC is authorized by the Trustees to manage a separate portion of the assets of the fund, as designated from time to time by Putnam Management or PIL. PAC did not manage any portion of the assets of the fund during the reporting period. If Putnam Management or PIL were to engage the services of PAC, Putnam Management or PIL, as applicable, would pay a quarterly sub-advisory fee to PAC for its services at the annual rate of 0.25% of the average net assets of the portion of the fund's assets for which PAC is engaged as sub-adviser.

The fund reimburses Putnam Management an allocated amount for the compensation and related expenses of certain officers of the fund and their staff who provide administrative services to the fund. The aggregate amount of all such reimbursements is determined annually by the Trustees.

Custodial functions for the fund's assets are provided by State Street. Custody fees are based on the fund's asset level, the number of its security holdings and transaction volumes.

Putnam Investor Services, Inc., an affiliate of Putnam Management, provides investor servicing agent functions to the fund. Putnam Investor Services, Inc. received fees for investor servicing for class A, class B, class C, class R and class Y shares that included (1) a per account fee for each direct and underlying non-defined contribution account (retail account) of the fund; (2) a specified rate of the fund's assets attributable to defined contribution plan accounts; and (3) a specified rate based on the average net assets in retail accounts. Putnam Investor Services, Inc. has agreed that the aggregate investor servicing fees for each fund's retail and defined contribution accounts for these share classes will not exceed an annual rate of 0.25% of the fund's average assets attributable to such accounts.

Class R6 shares paid a monthly fee based on the average net assets of class R6 shares at an annual rate of 0.05%.

During the reporting period, the expenses for each class of shares related to investor servicing fees were as follows:

Class A	\$1,943,500	Class R	2,805
Class B	8,953	Class R6	14,380
Class C	28,704	Class Y	226,736
		<b>Total</b>	<b>\$2,225,078</b>

The fund has entered into expense offset arrangements with Putnam Investor Services, Inc. and State Street whereby Putnam Investor Services, Inc.'s and State Street's fees are reduced by credits allowed on cash balances. For the reporting period, the fund's expenses were reduced by \$20,088 under the expense offset arrangements.

Each Independent Trustee of the fund receives an annual Trustee fee, of which \$1,325, as a quarterly retainer, has been allocated to the fund, and an additional fee for each Trustees meeting attended. Trustees also are reimbursed for expenses they incur relating to their services as Trustees.

The fund has adopted a Trustee Fee Deferral Plan (the Deferral Plan) which allows the Trustees to defer the receipt of all or a portion of Trustees fees payable on or after July 1, 1995. The deferred fees remain invested in certain Putnam funds until distribution in accordance with the Deferral Plan.

The fund has adopted an unfunded noncontributory defined benefit pension plan (the Pension Plan) covering all Trustees of the fund who have served as a Trustee for at least five years and were first elected prior to 2004. Benefits under the Pension Plan are equal to 50% of the Trustee's average annual attendance and retainer fees for the three years ended December 31, 2005. The retirement benefit is payable during a Trustee's lifetime, beginning the year following retirement, for the number of years of service through December 31, 2006. Pension expense for the fund is included in Trustee compensation and expenses in the Statement of operations. Accrued pension

liability is included in Payable for Trustee compensation and expenses in the Statement of assets and liabilities. The Trustees have terminated the Pension Plan with respect to any Trustee first elected after 2003.

The fund has adopted distribution plans (the Plans) with respect to the following share classes pursuant to Rule 12b-1 under the Investment Company Act of 1940. The purpose of the Plans is to compensate Putnam Retail Management Limited Partnership, an indirect wholly-owned subsidiary of Putnam Investments, LLC, for services provided and expenses incurred in distributing shares of the fund. The Plans provide payments by the fund to Putnam Retail Management Limited Partnership at an annual rate of up to the following amounts (Maximum %) of the average net assets attributable to each class. The Trustees have approved payment by the fund at the following annual rate (Approved %) of the average net assets attributable to each class. During the reporting period, the class-specific expenses related to distribution fees were as follows:

	Maximum %	Approved %	Amount
Class A	0.35%	0.25%	\$3,332,076
Class B	1.00%	1.00%	61,244
Class C	1.00%	1.00%	196,713
Class R	1.00%	0.50%	9,624
<b>Total</b>			<b>\$3,599,657</b>

For the reporting period, Putnam Retail Management Limited Partnership, acting as underwriter, received net commissions of \$62,689 from the sale of class A shares and received \$15 and \$246 in contingent deferred sales charges from redemptions of class B and class C shares, respectively.

A deferred sales charge of up to 1.00% is assessed on certain redemptions of class A shares. For the reporting period, Putnam Retail Management Limited Partnership, acting as underwriter, received \$129 on class A redemptions.

### Note 3: Purchases and sales of securities

During the reporting period, the cost of purchases and the proceeds from sales, excluding short-term investments, were as follows:

	Cost of purchases	Proceeds from sales
Investments in securities (Long-term)	\$603,295,082	\$763,382,423
U.S. government securities (Long-term)	—	—
<b>Total</b>	<b>\$603,295,082</b>	<b>\$763,382,423</b>

The fund may purchase or sell investments from or to other Putnam funds in the ordinary course of business, which can reduce the fund's transaction costs, at prices determined in accordance with SEC requirements and policies approved by the Trustees. During the reporting period, purchases or sales of long-term securities from or to other Putnam funds, if any, did not represent more than 5% of the fund's total cost of purchases and/or total proceeds from sales.

### Note 4: Capital shares

At the close of the reporting period, there were an unlimited number of shares of beneficial interest authorized. Transactions, including, if applicable, direct exchanges pursuant to share conversions, in capital shares were as follows:

Class A	YEAR ENDED 8/31/23		YEAR ENDED 8/31/22	
	Shares	Amount	Shares	Amount
Shares sold	604,148	\$33,943,730	604,150	\$37,408,412
Shares issued in connection with reinvestment of distributions	1,694,107	94,769,424	2,454,353	153,863,410
	2,298,255	128,713,154	3,058,503	191,271,822
Shares repurchased	(2,248,770)	(126,571,015)	(1,989,631)	(122,894,853)
<b>Net increase</b>	<b>49,485</b>	<b>\$2,142,139</b>	<b>1,068,872</b>	<b>\$68,376,969</b>

Class B	YEAR ENDED 8/31/23		YEAR ENDED 8/31/22	
	Shares	Amount	Shares	Amount
Shares sold	846	\$18,446	3,759	\$99,308
Shares issued in connection with reinvestment of distributions	58,526	1,233,166	93,953	2,501,040
	59,372	1,251,612	97,712	2,600,348
Shares repurchased	(197,946)	(4,300,323)	(156,344)	(4,336,181)
<b>Net decrease</b>	<b>(138,574)</b>	<b>\$(3,048,711)</b>	<b>(58,632)</b>	<b>\$(1,735,833)</b>

Class C	YEAR ENDED 8/31/23		YEAR ENDED 8/31/22	
	Shares	Amount	Shares	Amount
Shares sold	71,676	\$2,489,100	62,054	\$2,444,932
Shares issued in connection with reinvestment of distributions	73,485	2,491,142	106,342	4,256,871
	145,161	4,980,242	168,396	6,701,803
Shares repurchased	(245,222)	(8,380,538)	(209,357)	(8,479,763)
<b>Net decrease</b>	<b>(100,061)</b>	<b>\$(3,400,296)</b>	<b>(40,961)</b>	<b>\$(1,777,960)</b>

Class R	YEAR ENDED 8/31/23		YEAR ENDED 8/31/22	
	Shares	Amount	Shares	Amount
Shares sold	15,361	\$773,248	15,847	\$867,888
Shares issued in connection with reinvestment of distributions	2,919	146,942	3,402	193,721
	18,280	920,190	19,249	1,061,609
Shares repurchased	(15,598)	(803,568)	(19,746)	(1,109,608)
<b>Net increase (decrease)</b>	<b>2,682</b>	<b>\$116,622</b>	<b>(497)</b>	<b>\$(47,999)</b>

Class R6	YEAR ENDED 8/31/23		YEAR ENDED 8/31/22	
	Shares	Amount	Shares	Amount
Shares sold	74,569	\$4,637,906	363,426	\$24,061,580
Shares issued in connection with reinvestment of distributions	33,264	2,069,731	28,981	2,004,930
	107,833	6,707,637	392,407	26,066,510
Shares repurchased	(134,097)	(8,331,119)	(174,407)	(11,317,000)
<b>Net increase (decrease)</b>	<b>(26,264)</b>	<b>\$(1,623,482)</b>	<b>218,000</b>	<b>\$14,749,510</b>

Class Y	YEAR ENDED 8/31/23		YEAR ENDED 8/31/22	
	Shares	Amount	Shares	Amount
Shares sold	928,021	\$57,765,621	1,046,237	\$68,928,764
Shares issued in connection with reinvestment of distributions	184,107	11,429,504	173,547	11,985,185
	1,112,128	69,195,125	1,219,784	80,913,949
Shares repurchased	(1,120,660)	(69,476,671)	(361,648)	(24,030,351)
<b>Net increase (decrease)</b>	<b>(8,532)</b>	<b>\$(281,546)</b>	<b>858,136</b>	<b>\$56,883,598</b>

### Note 5: Affiliated transactions

Transactions during the reporting period with any company which is under common ownership or control were as follows:

Name of affiliate	Fair value as of 8/31/22	Purchase cost	Sale proceeds
<b>Short-term investments</b>			
Putnam Cash Collateral Pool, LLC*	\$84,524,981	\$340,374,529	\$374,447,745
Putnam Short Term Investment Fund**	45,137,290	384,582,156	344,871,728
<b>Total Short-term investments</b>	<b>129,662,271</b>	<b>724,956,685</b>	<b>719,319,473</b>
<b>Common stocks***</b>			
<b>Health care</b>			
4Front Ventures Corp.	27,882,348	—	—
Innoviva, Inc.	52,326,976	16,198,733	2,553,612
<b>Total Common stocks</b>	<b>80,209,324</b>	<b>16,198,733</b>	<b>2,553,612</b>
<b>Totals</b>	<b>\$209,871,595</b>	<b>\$741,155,418</b>	<b>\$721,873,085</b>

\* No management fees are charged to Putnam Cash Collateral Pool, LLC (Note 1). Investment income shown is included in securities lending income on the Statement of operations. There were no realized or unrealized gains or losses during the period.

\*\* Management fees charged to Putnam Short Term Investment Fund have been waived by Putnam Management. There were no realized or unrealized gains or losses during the period.

\*\*\* Common stock classifications are presented at the sector level, which may differ from the fund's portfolio presentation.

### Note 6: Market, credit and other risks

In the normal course of business, the fund trades financial instruments and enters into financial transactions where risk of potential loss exists due to changes in the market (market risk) or failure of the contracting party to the transaction to perform (credit risk). The fund may be exposed to additional credit risk that an institution or other entity with which the fund has unsettled or open transactions will default. Investments in foreign securities involve certain risks, including those related to economic instability, unfavorable political developments, and currency fluctuations.

The fund concentrates a majority of its investments in the health sector, which involves more risk than a fund that invests more broadly.

Investment income	Realized gain (loss)	Change in unrealized appreciation (depreciation)	Shares outstanding as of 8/31/23	Fair value as of 8/31/23
\$3,347,285	\$—	\$—	50,451,765	\$50,451,765
2,585,333	—	—	84,847,718	84,847,718
<b>5,932,618</b>	<b>—</b>	<b>—</b>		<b>135,299,483</b>
—	—	(21,545,451)	49,896,829	6,336,897
—	(836,788)	623,212	5,157,531	65,758,520
—	<b>(836,788)</b>	<b>(20,922,239)</b>	—	<b>72,095,417</b>
<b>\$5,932,618</b>	<b>\$ (836,788)</b>	<b>\$ (20,922,239)</b>	—	<b>\$ 207,394,900</b>

#### Note 7: Summary of derivative activity

The volume of activity for the reporting period for any derivative type that was held during the period is listed below and was based on an average of the holdings at the end of each fiscal quarter:

Forward currency contracts (contract amount)	\$563,800,000
--	---------------

The following is a summary of the fair value of derivative instruments as of the close of the reporting period:

#### Fair value of derivative instruments as of the close of the reporting period

Derivatives not accounted for as hedging instruments under ASC 815	ASSET DERIVATIVES		LIABILITY DERIVATIVES	
	Statement of assets and liabilities location	Fair value	Statement of assets and liabilities location	Fair value
Foreign exchange contracts	Receivables	\$2,084,067	Payables	\$2,273,359
<b>Total</b>		<b>\$2,084,067</b>		<b>\$2,273,359</b>

The following is a summary of realized and change in unrealized gains or losses of derivative instruments in the Statement of operations for the reporting period (Note 1):

#### Amount of realized gain or (loss) on derivatives recognized in net gain or (loss) on investments

Derivatives not accounted for as hedging instruments under ASC 815	Forward currency contracts	Total
Foreign exchange contracts	\$3,498,757	\$3,498,757
<b>Total</b>	<b>\$3,498,757</b>	<b>\$3,498,757</b>

#### Change in unrealized appreciation or (depreciation) on derivatives recognized in net gain or (loss) on investments

Derivatives not accounted for as hedging instruments under ASC 815	Forward currency contracts	Total
Foreign exchange contracts	\$(4,832,167)	\$(4,832,167)
<b>Total</b>	<b>\$(4,832,167)</b>	<b>\$(4,832,167)</b>

**Note 8: Offsetting of financial and derivative assets and liabilities**

The following table summarizes any derivatives, repurchase agreements and reverse repurchase agreements, at the end of the reporting period, that are subject to an enforceable master netting agreement or similar agreement. For securities lending transactions or borrowing transactions associated with securities sold short, if any, see Note 1. For financial reporting purposes, the fund does not offset financial assets and financial liabilities that are subject to the master netting agreements in the Statement of assets and liabilities.

	Bank of America N.A.	Citibank, N.A.	Goldman Sachs International	HSBC Bank USA, National Association
<b>Assets:</b>				
Forward currency contracts <sup>#</sup>	\$610,530	\$—	\$33,769	\$711,878
<b>Total Assets</b>	<b>\$610,530</b>	<b>\$—</b>	<b>\$33,769</b>	<b>\$711,878</b>
<b>Liabilities:</b>				
Forward currency contracts <sup>#</sup>	106,939	108,542	495,010	198,434
<b>Total Liabilities</b>	<b>\$106,939</b>	<b>\$108,542</b>	<b>\$495,010</b>	<b>\$198,434</b>
<b>Total Financial and Derivative Net Assets</b>	<b>\$503,591</b>	<b>\$(108,542)</b>	<b>\$(461,241)</b>	<b>\$513,444</b>
Total collateral received (pledged) <sup>†###</sup>	\$503,591	\$(108,542)	\$(461,241)	\$513,444
Net amount	\$—	\$—	\$—	\$—
<i>Controlled collateral received (including TBA commitments)**</i>	\$670,485	\$—	\$—	\$641,142
<i>Uncontrolled collateral received</i>	\$—	\$—	\$—	\$—
<i>Collateral (pledged) (including TBA commitments)**</i>	\$—	\$(371,819)	\$(493,707)	\$—

\*\* Included with Investments in securities on the Statement of assets and liabilities.

† Additional collateral may be required from certain brokers based on individual agreements.

# Covered by master netting agreement (Note 1).

## Any over-collateralization of total financial and derivative net assets is not shown. Collateral may include amounts related to unsettled agreements.

**Note 9: Of special note**

On May 31, 2023, Franklin Resources, Inc. (“Franklin Resources”) and Great-West Lifeco Inc., the parent company of Putnam U.S. Holdings I, LLC (“Putnam Holdings”), announced that they have entered into a definitive agreement for a subsidiary of Franklin Resources to acquire Putnam Holdings in a stock and cash transaction.

As part of this transaction, Putnam Management, a wholly-owned subsidiary of Putnam Holdings and investment manager to the Putnam family of funds (the “Putnam Funds”), would become an indirect wholly-owned subsidiary of Franklin Resources.

The transaction is subject to customary closing conditions, including receipt of applicable regulatory approvals. Subject to such approvals and the satisfaction of these conditions, the transaction is currently expected to be consummated in the fourth quarter of 2023.

Under the Investment Company Act of 1940, as amended, consummation of the transaction will result in the automatic termination of the investment management contract between each Putnam Fund and Putnam Management and any related sub-management and sub-advisory contracts, where applicable. In anticipation of this automatic termination, on June 23, 2023, the Board of Trustees of the Putnam Funds approved a new investment management contract between each Putnam Fund and Putnam Management (and new sub-management and sub-advisory contracts, if applicable), which will be presented to the shareholders of each Putnam Fund for their approval at shareholder meetings currently expected to occur in October 2023. Proxy solicitation materials related to these meetings have been made available to shareholders that held shares of the fund at the close of business on July 24, 2023.

JPMorgan Chase Bank N.A.	Morgan Stanley & Co. International PLC	NatWest Markets PLC	State Street Bank and Trust Co.	UBS AG	WestPac Banking Corp.	Total
\$99,352	\$144,978	\$—	\$463,000	\$20,560	\$—	\$2,084,067
<b>\$99,352</b>	<b>\$144,978</b>	<b>\$—</b>	<b>\$463,000</b>	<b>\$20,560</b>	<b>\$—</b>	<b>\$2,084,067</b>
174,925	203,280	615,612	—	239,069	131,548	2,273,359
<b>\$174,925</b>	<b>\$203,280</b>	<b>\$615,612</b>	<b>\$—</b>	<b>\$239,069</b>	<b>\$131,548</b>	<b>\$2,273,359</b>
<b>\$(75,573)</b>	<b>\$(58,302)</b>	<b>\$(615,612)</b>	<b>\$463,000</b>	<b>\$(218,509)</b>	<b>\$(131,548)</b>	<b>\$(189,292)</b>
\$(75,573)	\$—	\$(615,612)	\$463,000	\$(218,509)	\$—	
\$—	\$(58,302)	\$—	\$—	\$—	\$(131,548)	
\$—	\$—	\$—	\$571,637	\$—	\$—	\$1,883,264
\$—	\$—	\$—	\$—	\$—	\$—	\$—
\$(140,679)	\$—	\$(732,766)	\$—	\$(267,452)	\$—	\$(2,006,423)

## Federal tax information (Unaudited)

Pursuant to §852 of the Internal Revenue Code, as amended, the fund hereby designates \$86,632,251 as a capital gain dividend with respect to the taxable year ended August 31, 2023, or, if subsequently determined to be different, the net capital gain of such year.

The fund designated 100% of ordinary income distributions as qualifying for the dividends received deduction for corporations.

For the reporting period, the fund hereby designates 100%, or the maximum amount allowable, of its taxable ordinary income distributions as qualified dividends taxed at the individual net capital gain rates.

For the reporting period, pursuant to §871(k) of the Internal Revenue Code, the fund hereby designates \$193,495 of distributions paid as qualifying to be taxed as interest-related dividends for nonresident alien shareholders.

The Form 1099 that will be mailed to you in January 2024 will show the tax status of all distributions paid to your account in calendar 2023.

# About the Trustees

## INDEPENDENT TRUSTEES



### Liaquat Ahamed

*Born 1952, Trustee since 2012*

#### Principal occupations during past

**five years:** Author; won Pulitzer Prize for *Lords of Finance: The Bankers Who Broke the World*.

**Other directorships:** Chair of the Sun Valley Writers Conference, a literary not-for-profit organization, and a Trustee of the Journal of Philosophy.



### Barbara M. Baumann

*Born 1955, Trustee since 2010, Vice Chair since 2022*

#### Principal occupations during past

**five years:** President of Cross Creek Energy Corporation, a strategic consultant to domestic energy firms and direct investor in energy projects.

**Other directorships:** Director of Devon Energy Corporation, a publicly traded independent natural gas and oil exploration and production company; Director of National Fuel Gas Company, a publicly traded energy company that engages in the production, gathering, transportation, distribution, and marketing of natural gas; Senior Advisor to the energy private equity firm First Reserve; member of the Finance Committee of the Children's Hospital of Colorado; member of the Investment Committee of the Board of The Denver Foundation; and previously a Director of publicly traded companies Buckeye Partners LP, UNS Energy Corporation, CVR Energy Company, and SM Energy Corporation.



### Katinka Domotorffy

*Born 1975, Trustee since 2012*

#### Principal occupations during past

**five years:** Voting member of the Investment Committees of the Anne Ray Foundation and Margaret A. Cargill Foundation, part of the Margaret A. Cargill Philanthropies.

**Other directorships:** Director of the Great Lakes Science Center and of College Now Greater Cleveland.



### Catharine Bond Hill

*Born 1954, Trustee since 2017*

#### Principal occupations during past

**five years:** Managing Director of Ithaka S+R, a not-for-profit service that helps the academic community navigate economic and technological change. From 2006 to 2016, Dr. Hill served as the 10th president of Vassar College.

**Other directorships:** Director of Yale-NUS College and Trustee of Yale University.



### Kenneth R. Leibler

*Born 1949, Trustee since 2006, Vice Chair from 2016 to 2018, Chair since 2018*

#### Principal occupations during past

**five years:** Vice Chair Emeritus of the Board of Trustees of Beth Israel Deaconess Hospital in Boston. Member of the Investment Committee of the Boston Arts Academy Foundation.

**Other directorships:** Director of Eversource Corporation, which operates New England's largest energy delivery system; previously the Chairman of the Boston Options Exchange, an electronic marketplace for the trading of listed derivatives securities; previously the Chairman and Chief Executive Officer of the Boston Stock Exchange; and previously the President and Chief Operating Officer of the American Stock Exchange.



### Jennifer Williams Murphy

*Born 1964, Trustee since 2022*

#### Principal occupations during past

**five years:** Chief Executive Officer and Founder of Runa Digital Assets, LLC, an institutional investment advisory firm specializing in active management of digital assets. Until 2021, Chief Operating Officer of Western Asset Management, LLC, a global investment advisor, and Chief Executive Officer and President of Western Asset Mortgage Capital Corporation, a mortgage finance real estate investment trust.

**Other directorships:** Previously, a Director of Western Asset Capital Corporation.



### Marie Pillai

*Born 1954, Trustee since 2022*

#### Principal occupations during past

**five years:** Senior Advisor, Hunter Street Partners, LP, an asset-oriented private investment firm; Specialty Leader and Member of the Curriculum Committee of the Center for Board Certified Fiduciaries, a public benefit corporation providing coursework for developing fiduciaries. Until 2019, Vice President, Chief Investment Officer, and Treasurer of General Mills, Inc., a global food company.

**Other directorships:** Member of the Investment Committee of the Bush Foundation, a nonprofit organization supporting community problem-solving in Minnesota, North Dakota, and South Dakota; Member of the Finance Council and Corporate Board of the Archdiocese of Saint Paul and Minneapolis; previously a Board Member of Catholic Charities of St. Paul and Minneapolis; Director of the Catholic Community Foundation of Minnesota; and Investment Advisory Board Member of the University of Minnesota.



**George Putnam III***Born 1951, Trustee since 1984***Principal occupations during past****five years:** Chair of New Generation

Research, Inc., a publisher of financial advisory and other research services, and President of New Generation Advisors, LLC, a registered investment advisor to private funds.

**Other directorships:** Director of The Boston Family Office, LLC, a registered investment advisor; a Director of the Gloucester Marine Genomics Institute; a Trustee of the Lowell Observatory Foundation; and previously a Trustee of the Marine Biological Laboratory.

**Manoj P. Singh***Born 1952, Trustee since 2017***Principal occupations during past****five years:** Until 2015, Chief Operating

Officer and Global Managing Director at Deloitte Touche Tohmatsu, Ltd., a global professional services organization, serving on the Deloitte U.S. Board of Directors and the boards of Deloitte member firms in China, Mexico, and Southeast Asia.

**Other directorships:** Director of ReNew Energy Global plc, a publicly traded renewable energy company; Director of Abt Associates, a global research firm working in the fields of health, social and environmental policy, and international development; Trustee of Carnegie Mellon University; Director of Pratham USA, an organization dedicated to children's education in India; member of the advisory board of Altimetrik, a business transformation and technology solutions firm; and Director of DXC Technology, a global IT services and consulting company.

**Mona K. Sutphen***Born 1967, Trustee since 2020***Principal occupations during past five****years:** Partner, Investment Strategies, at

The Vistria Group, a private investment firm focused on middle-market companies in the health care, education, and financial services industries. From 2014 to 2018, Partner at Macro Advisory Partners, a global consulting firm.

**Other directorships:** Director of Spotify Technology S.A., a publicly traded audio content streaming service; Director of Unitek Learning, a private nursing and medical services education provider in the United States; Board Member, International Rescue Committee; Co-Chair of the Board of Human Rights First; Trustee of Mount Holyoke College; member of the Advisory Board for the Center on Global Energy Policy at Columbia University's School of International and Public Affairs; previously Director of Pattern Energy and Pioneer Natural Resources, publicly traded energy companies; and previously Managing Director of UBS AG.

**INTERESTED TRUSTEE****Robert L. Reynolds\****Born 1952, Trustee since 2008, President and Chief Executive Officer of Putnam Investments since 2008***Principal occupations during past five**

**years:** President and Chief Executive Officer of Putnam Investments; member of Putnam Investments' Board of Directors; and Chair of Great-West Lifeco U.S. LLC. Prior to 2019, also President and Chief Executive Officer of Great-West Financial, a financial services company that provides retirement savings plans, life insurance, and annuity and executive benefits products, and of Great-West Lifeco U.S. LLC, a holding company that owns Putnam Investments and Great-West Financial, and a member of Great-West Financial's Board of Directors.

**Other directorships:** Director of the Concord Museum; Director of Dana-Farber Cancer Institute; Director of the U.S. Ski & Snowboard Foundation; Chair of the Boston Advisory Board of the American Ireland Fund; Council Co-Chair of the American Enterprise Institute; Member of U.S. Chamber of Commerce, Center for Capital Markets Competitiveness; Chair of Massachusetts High Technology Council; Member of the Chief Executives Club of Boston; Member of the Massachusetts General Hospital President's Council; Chairman of the Board of Directors of the Ron Burton Training Village; Director and former Chair of the Massachusetts Competitive Partnership; former Chair of the West Virginia University Foundation; and former Executive Committee Member of the Greater Boston Chamber of Commerce.

\* Mr. Reynolds is an "interested person" (as defined in the Investment Company Act of 1940) of the fund and Putnam Investments. He is President and Chief Executive Officer of Putnam Investments, as well as the President of your fund and each of the other Putnam funds.

The address of each Trustee is 100 Federal Street, Boston, MA 02110.

As of August 31, 2023, there were 89 mutual funds, 4 closed-end funds, and 12 exchange-traded funds in the Putnam funds complex. Each Trustee serves as Trustee of all funds in the Putnam funds complex.

Each Trustee serves for an indefinite term, until his or her resignation, retirement at age 75, removal, or death.

## Officers

In addition to Robert L. Reynolds, the other officers of the fund are shown below:

**James F. Clark** *(Born 1974)*

Vice President and Chief Compliance Officer

*Since 2016*

Chief Compliance Officer and Chief Risk Officer, Putnam Investments, and Chief Compliance Officer, Putnam Management

**Michael J. Higgins** *(Born 1976)*

Vice President, Treasurer, and Clerk

*Since 2010*

**Jonathan S. Horwitz** *(Born 1955)*

Executive Vice President, Principal Executive Officer, and Compliance Liaison

*Since 2004*

**Richard T. Kircher** *(Born 1962)*

Vice President and BSA Compliance Officer

*Since 2019*

Assistant Director, Operational Compliance, Putnam Investments and Putnam Retail Management

**Martin Lemaire** *(Born 1984)*

Vice President and Derivatives Risk Manager

*Since 2022*

Risk Manager and Risk Analyst, Putnam Investments

**Susan G. Malloy** *(Born 1957)*

Vice President and Assistant Treasurer

*Since 2007*

Head of Accounting and Middle Office Services, Putnam Investments and Putnam Management

**Alan G. McCormack** *(Born 1964)*

Vice President and Derivatives Risk Manager

*Since 2022*

Head of Quantitative Equities and Risk, Putnam Investments

**Denere P. Poulack** *(Born 1968)*

Assistant Vice President, Assistant Clerk, and Assistant Treasurer

*Since 2004*

**Janet C. Smith** *(Born 1965)*

Vice President, Principal Financial Officer, Principal Accounting Officer, and Assistant Treasurer

*Since 2007*

Head of Fund Administration Services, Putnam Investments and Putnam Management

**Stephen J. Tate** *(Born 1974)*

Vice President and Chief Legal Officer

*Since 2021*

General Counsel, Putnam Investments, Putnam Management, and Putnam Retail Management

**Mark C. Trenchard** *(Born 1962)*

Vice President

*Since 2002*

Director of Operational Compliance, Putnam Investments and Putnam Retail Management

The principal occupations of the officers for the past five years have been with the employers as shown above, although in some cases they have held different positions with such employers. The address of each officer is 100 Federal Street, Boston, MA 02110.

## Fund information

Founded over 85 years ago, Putnam Investments was built around the concept that a balance between risk and reward is the hallmark of a well-rounded financial program. We manage funds across income, value, blend, growth, sustainable, and asset allocation categories.

### Investment Manager

Putnam Investment Management, LLC  
100 Federal Street  
Boston, MA 02110

### Investment Sub-Advisors

Putnam Investments Limited  
16 St James's Street  
London, England SW1A 1ER

The Putnam Advisory Company, LLC  
100 Federal Street  
Boston, MA 02110

### Marketing Services

Putnam Retail Management Limited Partnership  
100 Federal Street  
Boston, MA 02110

### Custodian

State Street Bank and Trust Company

### Legal Counsel

Ropes & Gray LLP

### Independent Registered Public Accounting Firm

PricewaterhouseCoopers LLP

### Trustees

Kenneth R. Leibler, *Chair*  
Barbara M. Baumann, *Vice Chair*  
Liaquat Ahamed  
Katinka Domotorffy  
Catharine Bond Hill  
Jennifer Williams Murphy  
Marie Pillai  
George Putnam III  
Robert L. Reynolds  
Manoj P. Singh  
Mona K. Sutphen

### Officers

Robert L. Reynolds  
*President*

James F. Clark  
*Vice President and Chief Compliance Officer*

Michael J. Higgins  
*Vice President, Treasurer, and Clerk*

Jonathan S. Horwitz  
*Executive Vice President, Principal Executive Officer, and Compliance Liaison*

Richard T. Kircher  
*Vice President and BSA Compliance Officer*

Martin Lemaire  
*Vice President and Derivatives Risk Manager*

Susan G. Malloy  
*Vice President and Assistant Treasurer*

Alan G. McCormack  
*Vice President and Derivatives Risk Manager*

Denere P. Poulack  
*Assistant Vice President, Assistant Clerk, and Assistant Treasurer*

Janet C. Smith  
*Vice President, Principal Financial Officer, Principal Accounting Officer, and Assistant Treasurer*

Stephen J. Tate  
*Vice President and Chief Legal Officer*

Mark C. Trenchard  
*Vice President*

*This report is for the information of shareholders of Putnam Global Health Care Fund. It may also be used as sales literature when preceded or accompanied by the current prospectus, the most recent copy of Putnam's Quarterly Performance Summary, and Putnam's Quarterly Ranking Summary. For more recent performance, please visit [putnam.com](http://putnam.com). Investors should carefully consider the investment objectives, risks, charges, and expenses of a fund, which are described in its prospectus. For this and other information or to request a prospectus or summary prospectus, call 1-800-225-1581 toll free. Please read the prospectus carefully before investing. The fund's Statement of Additional Information contains additional information about the fund's Trustees and is available without charge upon request by calling 1-800-225-1581.*

